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Abstract 
Background 
Non-communicable diseases (NCD’s) are on the rise in patients with HIV and this has been 
partly attributed to the increasing use of Antiretroviral therapy (ART). Our aim was to 
consolidate findings on prevalence of NCD in those with HIV, from systematic reviews, to 
inform the existing body of research and provide evidence to inform planning of healthcare 
services. 
Methods 
We undertook a comprehensive search in February 2018, with no date limitations, in 7 
databases to identify systematic reviews on the prevalence of NCD’s in HIV patients on 
ART. We included systematic reviews with participants over the age of 13years who were 
on ART and had one or more of the specified NCD’s including diabetes mellitus type 2, 
hypertension, dyslipidemia and depression. We then assessed the quality of these systematic 
reviews using the AMSTAR 2 tool and extracted prevalence’s of the NCD’s from each one of 
them. 
Results 
We identified 10 systematic reviews meeting our inclusion criteria of which 3 are ongoing. 
The methodological quality of the seven systematic reviews assessed varied in many aspects. 
Only one systematic review assessed prevalence of multi-morbidity defined as the presence 
of two or more NCD’s in people living with HIV (PLHIV) which ranged from 8.4% to 47%, 
the remaining six only assessed the prevalence of comorbidity of any one NCD in PLHIV. 
Diabetes mellitus type 2 had the lowest prevalence especially in African countries and it 
ranged between 7% to 48.6% globally while dyslipidemia had the highest prevalence globally 
ranging from 6.3% to 100%. Depression in PLHIV who were on ART was considerably high 
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ranging from 25.81% to 64% while hypertension ranged from as low as 4.0% to as high as 
67.0%. 
Conclusions 
This overview highlights that NCD’s are highly prevalent in PLHIV on ART. There is a lack 
of systematic reviews and primary studies focusing on multi-morbidity in the HIV population 
on ART. 
PROSPERO registration number - CRD42018104420 
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Background 
The global prevalence of human immunodeficiency virus (HIV) has increased from 33.3 
million people in 2010 to 36.7 million people approximately by the end of 2015. Over the 
years, the use of combined Antiretroviral Therapy (ART) has reduced mortality from 
acquired immunodeficiency syndrome (AIDS). Deaths from AIDS reduced from 1.5 million 
in 2010 to 1.1 million by the end of 2015. Also, life expectancy has increased due to the 
several mechanisms through which ART suppress viral replication, reduce the occurrence of 
opportunistic infections and improve immune function. It has been documented that the use 
of ART has led to a stability in the acquisition of new HIV infections amongst all ages. The 
number of new infections dropped by a million people from 2.2 to 2.1 million in 2010 and 
2015 respectively (1). This may aid the United Nations Program on HIV and AIDS 
(UNAIDS) to achieve their 90-90-90 goal of ending the AIDS epidemic. 
However, with increased life expectancy, aging is inevitable and thus the diseases associated 
with aging such as cardiovascular abnormalities, hypertension, insulin resistance/diabetes 
mellitus, cholesterol abnormalities, neurodegenerative disorders and so forth occur. Research 
suggests the emergence of such diseases much earlier in the HIV population than seen in the 
general population (2)(3). For instance a cross-sectional study done in the United States (US) 
in 2010 showed that older HIV patients had a higher prevalence of hypertension 54%, 
hypertriglyceridemia 51% and low bone mineral density 39% compared to the general 
population of the same age 38%, 33% and 0% respectively (4). Another cross-sectional study 
done in Brazil suggested that there is premature aging in people living with HIV (PLHIV) by 
15 years and that HIV is diagnosed at an early age between 18-39years (5) leading to 
increased ART use in the older population and increasing the incidence of non-communicable 
diseases (NCD’s) such as hypertension, dyslipidemia, diabetes mellitus, obesity and 
depression with older age (5), (6), (7) due to prolonged exposure to ART. 
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Aging is not the only mechanism leading to the development of NCD’s, these findings can be 
attributed to the disease process itself via its viral properties or the inflammation and reaction 
by the human body, and to the toxic effects of the ART which lead to ART induced 
endothelial dysfunction as shown by a systematic review done by Nduka CU et al (8). Also, 
studies reveal that the number of years since the diagnosis of HIV and the duration and type 
of ART received is crucial in the development of NCD’s. A cross-sectional study done in 
Mwanza region of Tanzania in 2013 showed that PLHIV on ART for more than 2 years had a 
prevalence of 28.7% for hypertension while those naïve to ART had a prevalence of 5.3% 
(9). 
Another important aspect of ART is the type of ART in question, it has been shown that 
people receiving a combination of Zidovudine/Lamivudine/Nevirapine (1st line treatment) are 
at an increased risk of hypertension while those receiving the non-standard 1st line treatment 
or the 2nd line drugs are at increased risk of Diabetes (10). Long duration of ART and usage 
of protease inhibitors have been associated with an increased risk of metabolic syndrome 
(11).  
Because of the slow progress in the decline of new HIV infections amongst adults (12), it has 
become a chronic problem and is being more associated with NCD’s at younger ages than in 
the general population. A huge burden of HIV of about 71% lies in the Sub-Saharan Africa 
(SSA) which is home to only about 12% of the global population (13) with marked ART 
coverage over the last few years in different countries (12) as we aim to reach the 90-90-90 
target set by the UNAIDS thus putting patients at the risk of developing NCD’s earlier 
indefinitely.  
Models which integrate NCD’s within the HIV setting have been identified which include 
screening for HIV along with NCD’s in the general population, screening for NCD’s or its 
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risk factors in HIV patients attending HIV care, integration HIV and NCD care in clinics 
where patients have both of the conditions, differentiated care for patients who have HIV 
and/or NCD and integrated healthcare for all patients providing benefits of nutrition and so 
forth which affects HIV/NCD outcomes(14)(15)(16). However, because HIV linked to NCD 
is a relatively new concept, integration of screening for risk factors/existing NCD’s and its 
treatment is challenging due to inefficient evidence, lack of funding and poor capacity to 
support such models of care due to the different disease priorities set by different nations 
(17)(18)(19). There have been many systematic reviews done on the prevalence of 
comorbidities in patients with HIV with varying results in different populations (20)(21)(22) 
For instance the prevalence of diabetes mellitus was found to be the lowest in most 
systematic reviews while hypertension and cardiovascular diseases were more prevalent with 
broader range of values (22)(23). However, we cannot ascertain the quality of evidence for 
these systematic reviews. Hence our aim was to consolidate all the available findings to 
summarize the global prevalence of co- and multi-morbidity with one or more NCD’s namely 
diabetes mellitus type 2, hypertension, dyslipidemia and depression in adults with HIV on 
ART in order to provide information to health institutions for planning and integration of 
healthcare services. Also, new primary studies need to be informed by the existing body of 
research.  
 
Methods 
This is an overview of systematic reviews summarizing information from multiple systematic 
reviews following general principles using the Cochrane handbook version 5.1.0.  
The protocol for this study was registered in PROSPERO with the registration number 
CRD42018104420. 
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Selection Criteria 
We included systematic reviews conducted globally comprising of primary studies from any 
region in the world which assessed the prevalence of NCD’s using cross-sectional study 
designs in adults with HIV who were on treatment with any regimen of ART and excluded 
systematic reviews in which pregnant women were the study population. Cross-sectional 
studies in which groups of participants were being compared for the prevalence of NCD’s 
were included only if the said group comprised of participants who were on ART. We also 
reviewed the protocols of ongoing systematic reviews that meet our inclusion criteria and will 
include their results in this overview if they are completed prior to publishing it. Systematic 
reviews are defined as studies that answer a research question by collecting and summarizing 
all empirical evidence that fits pre-specified eligibility criteria. It must have its objectives 
stated a priori and should have searched for studies on two or more databases including grey 
literature/unpublished work. Extracted data should have been analyzed, and a risk of bias 
assessed for each study with results presented appropriately (24). 
Our primary outcome was to assess the prevalence of multi morbidity with diabetes mellitus 
type 2, hypertension, dyslipidemia and depression in adults with HIV on ART while the 
secondary outcomes of our study were to assess the prevalence of co morbidity with any of 
the above mentioned NCD’s in adults with HIV on ART; and, to identify the distribution of 
these NCD’s according to demographics such as age, gender, duration and type of ART.  
 
Definitions 
Multi morbidity is defined as the existence of two or more chronic medical conditions in a 
person that reduces his quality of life and functional abilities leading to increased hospital 
visits (25). The presence of HIV along with two or more NCD’s is described as multi 
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morbidity while the presence of one chronic disease in a patient with HIV is described as 
comorbidity in this systematic review. 
Diabetes mellitus type 2 is a chronic disease which is characterized by hyperglycemia due to 
the body’s inability to effectively utilize insulin, and, uncontrolled diabetes over time may 
lead to severe damage especially to the nerves and blood vessels. The diagnosis of diabetes is  
made by doing fasting blood glucose (FBG) > 7mmol/L, random blood glucose of > 
11.1mmol/L, glycated hemoglobin (HbA1c) > 6.5mmol/L or a two hour oral glucose 
tolerance test (OGTT) of > 11.1mmol/L (26).  
Hypertension is defined as persistently raised systolic and/or diastolic blood pressures of 
>140mmHg and >90mmHg respectively. Patients with raised blood pressures or identified 
using any antihypertensive medications are diagnosed to be hypertensive (27).  
Depression is part of a range of depressive disorders which are characterized by the presence 
of sad, empty, or irritable mood, accompanied by somatic and cognitive changes that 
significantly affect the individual's capacity to function. The Diagnostic and Statistical 
Manual of Mental Disorders Fifth Edition (DSM-5TM) has grouped the following under 
depressive disorders: disruptive mood dysregulation disorder, major depressive disorder 
(including major depressive episode), persistent depressive disorder (dysthymia), 
premenstrual dysphoric disorder, substance/medication-induced depressive disorder, 
depressive disorder due to another medical condition, other specified depressive disorder, and 
unspecified depressive disorder (28).  
Dyslipidemia is defined as elevated total serum cholesterol of > 5mmol/L or elevated low 
density lipoproteins (LDL) of > 3mmol/L or raised Triglycerides > 1.7mmol/L or low levels 
of high density lipoproteins (HDL) < 1.2mmol/L. Measuring the lipid profile or self-reported 
use of lipid lowering drugs by the patients can be used to confirm the diagnosis (29).  
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Search Strategy 
With assistance from an information specialist, we conducted a search for existing systematic 
reviews in 7 databases including the MEDLINE, Cochrane Database of Systematic Reviews 
(CDSR), Database of Abstracts of Reviews of Effects (DARE), Cumulative Index to Nursing 
and Allied Health Literature (CINAHL) and EBSCOHost, Web of Science, Epistemonikos and, 
in PROSPERO to identify any ongoing systematic reviews. We did not apply any restrictions 
to date, language or publication status in our search. However, we did not further look for 
systematic reviews from other sources such as reports nor contacted any specialists. Terms that 
we used to inform our search included those for non-communicable diseases, HIV, ART, 
systematic reviews, Type 2 diabetes mellitus, Hypertension, Depression, and Dyslipidemia 
(Additional file 1). 
 
Selection of systematic reviews 
Two authors (SJ and TY) independently assessed the eligibility of the articles obtained from 
the electronic search by screening through their titles and abstracts to determine potentially 
eligible systematic reviews. We then obtained full texts for screening and applied the pre-
specified eligibility criteria in order to include these systematic reviews in our overview. Any 
discrepancy in the selection of studies was resolved by discussion between the two authors. 
 
Data extraction and management 
One author (SJ) extracted data from the included systematic reviews into a predesigned and 
piloted data extraction form. The second author (TY) checked the data that were extracted 
which included:  
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- Characteristics of the systematic reviews including their study designs, when was it 
conducted, how many primary and specifically cross-sectional studies did it include, 
where have the cross-sectional studies been conducted and what its objectives are. 
- Participants’ characteristics including age groups, gender and types/classes of ART’s 
being used. 
- Results of the reviews i.e. the prevalence of each type of NCD assessed and the 
prevalence of two or more NCD’s in PLHIV. 
We summarized data from each systematic review in the table of characteristics of included 
systematic reviews (Tables 1 and 2) and also did a mapping of cross-sectional studies from 
each systematic review (Table 3) to identify an overlap of cross-sectional studies between the 
systematic reviews.  
 
Assessment of methodological quality of included systematic reviews 
We assessed the methodological quality of each of the included systematic reviews using the 
AMSTAR 2 tool (30) which is a revision of the AMSTAR tool in order to identify high 
quality systematic reviews. AMSTAR 2 is a critical appraisal tool for systematic reviews that 
include randomized or non-randomized studies of health care interventions. It consists of 16 
domains which must be answered with a yes, partial yes or a no (30). Not all the domains of 
the AMSTAR 2 tool have been addressed because some of them are only applicable to 
intervention studies. Hence, we only answered questions in the domains that are pertinent to 
appraising the quality of systematic reviews in general. We did not generate an overall score 
for each of the included systematic review, but rather considered the potential impact of an 
inadequate rating for each item.  
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We resolved discrepancies in the data extracted from the systematic reviews by obtaining the 
cross-sectional study which was included in the systematic review and reviewing its findings. 
Disagreements between the two authors (SJ and TY) were solved by discussion with each 
other. 
 
Data analysis 
Because of the nature of the primary studies involved we provide a narrative summary of our 
findings considering all the participants, their NCD and ART status. We report on the 
prevalence of each type of NCD identified as well as the prevalence of two or more NCD’s in 
PLHIV with its 95% confidence interval as reported in the included systematic reviews.  
 
Results  
Description of included systematic reviews 
Our search yielded a total of 1600 articles (Figure 1) and after deduplication and screening, 
we remained with 10 systematic reviews for inclusion in this overview. The major reasons for 
excluding articles include systematic reviews which did not assess the prevalence of NCD’s 
using cross-sectional study designs instead they measured incidence/association and included 
other primary study designs, or their participants were not on ART or they included children 
and pregnant women (Table 4). Because of the different cut offs used for age within the 
included systematic reviews, we included participants from the age of 13 years onwards. 
Most of the systematic reviews that we have included comprise of HIV participants who were 
on ART and those who were ART naïve, hence, we have only considered the results of those 
in the ART group. 
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In this overview, the included systematic reviews were conducted between 2009 and 2017. 
Seven out of the 10 systematic reviews which meet our inclusion criteria have been 
completed. They are included in the Table of complete systematic reviews (Table 1) while 3 
of them are ongoing systematic reviews (Table 2). The completed systematic reviews include 
a combination of observational studies including cohort, case control and cross-sectional 
study designs hence we have mapped out only cross-sectional studies as per our criteria to 
observe their overlap within the included systematic reviews. 
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Figure 1 – PRISMA Flow diagram 
 
 
Table 1: Completed Systematic Reviews 
1600 articles generated - 27 February 2018 
(MEDLINE, CDSR, DARE, CINAHL, Web 
of Science, PROSPERO, Epistemonikos) 
 
-  
 
 
 
149 duplicates removed 
1451 titles and abstracts screened 
1399 studies found to be irrelevant  
52 full texts assessed for eligibility 
42 studies excluded:  
- 22 not the  outcomes of interest 
- 9 assessed association between NCDs 
and HIV not prevalence 
- 7 not cross-sectional study designs  
- 2 clinical guidelines 
- 1 separate groups of 
HIV/ART/Hypertension were matched  
- 1 assessed prevalence of metabolic 
syndrome but did not report on its 
components 
 
10 reviews included 3 ongoing reviews 
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Study ID Review question  Date of 
the 
search 
No. of 
primary 
studies 
included 
No. of 
cross-
sectional 
studies 
within 
the 
review 
Population 
description  
Prevalence of the 
type of NCD on 
ART 
Bernard 
2017 (31) 
Prevalence and factors 
associated with 
depression in people living with 
HIV in Sub-Saharan Africa: A 
systematic review and meta- 
analysis 
April 
2016 
66 61 Adults; 
SSA 
Depression 
Brandt 
2009 (32) 
The mental health of people 
living with HIV/AIDS 
in Africa: a systematic review 
August 
2008 
 
24 19 Adults; 
SSA 
Depression 
Lowther 
2014 (33) 
Experience of persistent 
psychological symptoms and 
perceived stigma among people 
with HIV on antiretroviral 
therapy (ART): A systematic 
review  
August 
2013 
 
66 43 Adults and 
children; 
HIC and 
LMIC 
Depression 
Naidu 
2017 (34) 
Prevalence of Metabolic 
Syndrome Among People 
Living with HIV in Developing 
Countries: 
A Systematic Review  
April 
2015 
 
18 15 
 
Adults; 
Africa, 
Asia, South 
America 
Diabetes, 
Hypertension, 
Hypertriglyceridemia, 
low HDL  
Nguyen 
2015 (35) 
Burden, Determinants, and 
Pharmacological 
Management of Hypertension in 
HIV-Positive Patients and 
Populations: A Systematic 
Narrative Review 
February 
2015 
 
101 34 Adults; 
HIC and 
LMIC 
Hypertension  
Prioreschi 
2017 (36) 
Incidence and prevalence of 
type 2 diabetes mellitus with 
HIV infection in 
Africa: a systematic review and 
meta- analysis  
May 2016  
 
20 13 Adults; 
Africa 
Diabetes 
Xu 2017 
(37) 
Global prevalence of 
hypertension among people 
living with HIV: a systematic 
review and 
meta-analysis 
December 
2016 
 
49 36 Adults; 
America, 
Africa, 
Europe, 
Asia 
Hypertension  
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Table 2: Ongoing Systematic Reviews 
Study 
ID 
Review question Prevalence of the type of NCD on 
ART 
Bigna 
2017 
(38) 
Prevalence and incidence of hypertension in the global 
HIV-infected population: a systematic review and 
meta-analysis protocol  
Hypertension 
Bigna 
2018 
(39) 
Prevalence and incidence of major depressive disorders 
among people living with HIV residing in Africa: a 
systematic review and meta-analysis protocol  
Major depressive disorder 
Olamide 
2016 
(39) 
Prevalence of metabolic syndrome, discrete or 
comorbid diabetes and hypertension in sub-Saharan 
Africa among people living with HIV versus HIV-
negative populations: a systematic review and meta-
analysis protocol  
Diabetes, Hypertension, 
Hypertriglyceridemia, low HDL 
 
A total of 142 cross-sectional studies (Table 3) are contained within the completed systematic 
reviews and they have been conducted in 6 continents including Africa, Asia, North America, 
South America, Europe and Australia with majority of them capturing data from low and 
middle-income countries (LMIC). African countries in which these cross-sectional studies 
have been conducted include Ethiopia, Kenya, Malawi, Rwanda, Tanzania, Uganda and 
Zambia from Eastern Africa, Cameroon and Zaire/Democratic Republic of the Congo from 
Central Africa, Gambia, Mali, Nigeria and Senegal from Western Africa, And Botswana, 
Namibia and South Africa from Southern Africa. while the remaining were conducted in 
Australia, Brazil, Canada, China, Croatia, Ecuador, France, Germany, Hungary, India, Italy, 
Jamaica, Malaysia, Netherlands, Portugal, Serbia, Spain, Sweden, Taiwan, Thailand, United 
States and Vietnam.  
 
The initial number of primary studies within the systematic review was 178, however, 
because some of them involved HIV positive and negative participants and those who were 
HIV positive were not on ART, or the study design was a survey conducting a census on the 
population at large with unconfirmed ART status and sub-group information, or some of the 
primary studies were not cross-sectional studies as mentioned in the review and rather a 
cohort study design had been employed with no baseline data, we excluded them from this 
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overview. We also excluded cross-sectional studies for which we could not ascertain the ART 
status of the participants even after obtaining full texts of the articles. Of note, cross-sectional 
studies which included 2 arms; one of HIV positive and the other one of HIV negative 
participants, we retained those studies in which the HIV positive participants were on ART 
and if the two arms were patients on ART and ART naïve then we also retained them in the 
table. With regards to the proportion of people on ART in each of these cross-sectional 
studies, we observed that not all of them were able to find all patients who were on ART and 
thus the percentage of participants in totality between all the cross-sectional studies ranged 
from 18% to 100%. However, half of the cross-sectional studies (50%) have reported ART 
use of 100% in their participants. 
 
We only found one systematic review (Naidu 2017) which included 17 cross-sectional 
studies, assessing the prevalence of multimorbidity i.e. dyslipidemia, diabetes mellitus type 2 
and hypertension in patients with HIV on ART. Cross-sectional studies in this systematic 
review were conducted in African, Asian and South American countries including Botswana, 
Cameroon, Ethiopia, South Africa, India, Thailand, Argentina, Brazil, Colombia, Ecuador, 
Peru and Venezuela. , Of the 6 systematic reviews that assessed the prevalence of co-
morbidity,3 of them looked at depression amongst the HIV population,2 assessed the 
prevalence of hypertension and only 1 sought to look at the burden of diabetes mellitus 
(Table 1).  
 
We found some amount of overlap of cross-sectional studies between the systematic reviews 
whereby 28 were included in more than one systematic review. Of note, only the cross-
sectional study conducted by Poupard et al (40) are referenced in 3 systematic reviews while  
28 of them are  referenced in two systematic reviews (Table 3). 
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Quality of included reviews (AMSTAR) 
We assessed the quality of systematic reviews included in this overview using the AMSTAR 
2 tool (30). We only used questions pertaining to systematic reviews of cross-sectional 
studies (11 domains out of 16 were assessed) (Table 5 and Additional file 2). All the 
systematic reviews had clear research questions in terms of population and outcomes of 
interest, which then led to a good elaboration of the included cross-sectional studies in terms 
of the PICOT (population, intervention, comparator, outcome and time frame) elements 
within their table of included studies. Two systematic reviews (41)(33) did not provide very 
detailed information in their table of included studies and thus received partial yes scores. 
None of the systematic reviews provided a table of excluded studies.  
 
All but two of the systematic reviews (35),(36) did not mention anything about developing a 
protocol with review methods being determined a priori, and only one systematic review (36) 
provided their protocol registration number while for the other (35) the corresponding author 
confirmed the existence of a protocol which was not registered. All of the systematic review 
authors did not search comprehensively as they all scored a partial yes because either they did 
not search grey literature, reference lists, contacted experts in the field etc. or, only searched 
in one database. Screening and data extraction were not very clearly described in majority of 
the systematic reviews as there was uncertainty whether it was done by 2 independent 
authors. Only one systematic review (36) performed screening and data extraction as per the 
standards while another (34) screened appropriately however their method of data extraction 
is not clear. Screening in Lowther (33) and Xu (42) et al was done by one author.  
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All did not report funding for the cross-sectional studies included in their systematic reviews, 
however, they all reported on their own funding sources and declared conflicts in their 
systematic reviews as per the requirements of systematic reviews. All, but one systematic 
review (36) explored reasons around heterogeneity in their results, and 3 (31),(36),(34) of 
them went on to do a meta-analysis to show the pooled prevalence’s from the primary 
studies. However, authors that performed meta-analysis in their systematic reviews failed to 
report on publication bias in their findings and the rest of them did not mention it. In 
summary, the quality of the evidence base from these systematic reviews would be 
considered to be of low to moderate as key aspects related to their methods including 
conducting the search, screening and data extraction etc. are not clearly emphasized on.  
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Table 5: AMSTAR 2 – Assessment of the quality of included systematic reviews 
AMSTAR 2 Criteria Bernard 
2017 
Brandt 
2009 
Lowther 
2014 
Naidu 
2017 
Nguyen 
2015 
Priores-
chi 
2017 
Xu 
2017 
Did the research questions and 
inclusion criteria for the review 
include the components of 
PICO? Was the research 
question clear? 
 
       
Did the report of the review 
contain an explicit statement 
that the review methods were 
established prior to the conduct 
of the review and did the report 
justify any significant 
deviations from the protocol? 
       
Did the review authors use a 
comprehensive literature search 
strategy? 
 
 
       
Did the review authors perform 
study selection in duplicate? 
 
 
       
Did the review authors perform 
data extraction in duplicate? 
 
 
       
Did the review authors provide 
a list of excluded studies and 
justify the exclusions? 
 
 
       
Did the review authors describe 
the included studies in adequate 
detail? 
 
  
 
 
      
Did the review authors report 
on the sources of funding for 
the studies included in the 
review? 
 
        
Did the review authors provide 
a satisfactory explanation for, 
and discussion of, any 
heterogeneity observed in the 
results of the review? 
 
       
If they performed quantitative 
synthesis did the review authors 
 NA NA NA NA   
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Color coding:  
Yes = Dark green           Partial Yes = Light green          No = Red           Unclear = Yellow  
 
 
Prevalence of multi morbidity and comorbidities 
Prevalence of multi morbidity in people living with HIV (PLHIV) on ART 
We only found one systematic review which assessed the prevalence of multi morbidity in 
PLHIV  (34). Metabolic syndrome (MS) in this study has been defined as the presence of the 
risk factors which include hypertension, hyperglycemia, hypertriglyceridemia, low high-
density lipoprotein (HDL) cholesterol, and abdominal obesity which are associated with an 
increased risk of cardiovascular disease (CVD) and type II diabetes mellitus when in 
conjunction (43). They found an overall prevalence of MS in developing countries ranging 
from 8.4% to 47% with the mean prevalence of MS in South America being 21.4%, that of 
Asia as 21.5% and the highest in Africa which was 30.5%.  
 
This systematic review included 18 cross-sectional studies of which we excluded one from 
Table 3 as the study population was ART naïve. The remaining 17 cross-sectional studies 
included patients that were either all on ART (6 out of 11) or they were grouped as those 
receiving ART and ART naïve for which comparisons were made between the groups. On 
comparing the prevalence of MS in patients taking ART and those naïve to ART, only one 
out of the 8 cross-sectional studies reported a low prevalence of MS in the former group 
carry out an adequate 
investigation of publication bias 
(small study bias) and discuss 
its likely impact on the results 
of the review? 
Did the review authors report 
any potential sources of conflict 
of interest, including any 
funding they received for 
conducting the review? 
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(19.1% vs 21.7%). Ten of the cross-sectional studies also compared prevalence of MS 
according to gender and 80% of these reported a higher prevalence of MS in females which 
ranged from 18.7% to 46.8%. This systematic review further describes the prevalence of each 
of the components of MS in PLHIV which will be discussed in the section below. 
 
 
Prevalence of co-morbidity in PLHIV on ART  
Depression in PLHIV on ART 
We found that the prevalence of depression in PLHIV on ART has been reported by 3 
systematic review (41),(33),(31). A total of 77 cross-sectional studies form part of these 
systematic reviews of which Brandt 2009 only contributes 5 because of reasons explained 
earlier. Major Depressive Disorders (MDD) in these cross-sectional studies was assessed 
using the Mini-International Neuropsychiatric Interview (MINI) whereas for depression and 
depressive symptoms the Beck Depression Inventory (BDI), the CES-D (Centre for 
Epidemiological Studies depression tool), Hospital Anxiety and Depression scale (HADS), 
Patient Health Questionnaire (PHQ-9) and the Hopkins Symptom Checklist (HSCL-D) were 
used.  
Lowther et al (33) reports a point prevalence of depression ranging from 25.81% in high 
income countries to 41.36% in low- and middle-income countries with a mean of 33.6%. 
Bernard et al (31) on the other hand report on MDD and depressive symptoms. They reported 
that the prevalence of MDD in PLHIV on ART ranged between 3% to 14.2%. The prevalence 
of depressive symptoms was assessed for each tool used, some of which were pooled together 
in a meta-analysis to give a pooled prevalence. The pooled prevalence of depressive 
symptoms in PLHIV on ART using the CES-D tool found to be 32% with a high between 
group heterogeneity. Using the PHQ-9 tool the pooled prevalence of depressive symptoms in 
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PLHIV on ART was found to be 14% with a high between group heterogeneity. The BDI tool 
gave a high pooled prevalence of 43% with no between group heterogeneity. Using the 
HSCL tool, the pooled prevalence of depressive symptoms was found to be 13% with a low 
between group heterogeneity. Brandt 2009 (41) reports a high prevalence of depressive 
symptoms ranging from 30% to 64% in the African population using the tools described 
above.  
Type 2 Diabetes Mellitus in PLHIV on ART 
We only found one systematic review (36) which reported on the prevalence of type 2 
Diabetes in PLHIV on ART. This systematic review included 20 primary studies of which 6 
cross-sectional studies met our inclusion criteria. Five of these compared HIV patients on 
ART with ART naïve while one compared HIV positive patients on ART with HIV negative 
patients. Apart from the WHO diagnostic criteria for diagnosing diabetes type II, other 
criteria used include American Diabetes Association (ADA), National Cholesterol Education 
Program (NCEP) and International Diabetes Federation (IDF). Prioreschi et al (36) did not 
report on the prevalence of type II diabetes mellitus. Instead they calculated a risk ratio (RR) 
for participants on ART treatment compared to those not on ART which included a total of 5 
cross-sectional studies. The pooled RR is 1.38 which is not statistically significant (RR=1.38, 
95% CI 0.66 to 2.87, p=0.39). 
Naidu et al (34) is the systematic review which reported on MS and its components, 
hyperglycemia being one of them. The prevalence of hyperglycemia ranged between 7 to 
48.6% with a mean prevalence of22.5%. Whilst assessing continent wise, they found that the 
mean prevalence of hyperglycemia in Africa was 18.1%, South America 21.4% and in 23.4% 
in Asia. The authors did not provide with a numerical value but reported that 5 out of 7 
studies in which they compared patients on ART to ART naïve had higher prevalence’s of 
type II diabetes mellitus.  
Stellenbosch University  https://scholar.sun.ac.za
28 
 
 
Dyslipidemia in PLHIV on ART 
Naidu et al (34) assessed the prevalence of metabolic syndrome in PLHIV. Low HDL 
cholesterol and Hypertriglyceridemia are 2 of the components of Metabolic syndrome which 
fall under the diagnosis of dyslipidemia. They reported that the prevalence of low HDL 
cholesterol from 16 studies ranged from 6.3% to 100% with a mean of 50.1%. Continent 
wise, the mean prevalence of low HDL cholesterol was almost equal between South America 
and Asia (50.1% and 53.2% respectively) while Africa had a lower prevalence of 32.8%. Out 
of seven studies compared for which they did not provide any numerical data, they found that 
5 of them had higher prevalence’s of low HDL cholesterol in ART naïve patients. 
 
In the same systematic review (34), the prevalence of hypertriglyceridemia was estimated 
from 15 studies for which the range is 11.5% to 93.8% with a mean of 45.7%. In ascending 
order, the prevalence’s per continent were found to be 24.9%, 45.8% and 54.4% in Africa, 
Asia and South America respectively. To determine whether patients who are on ART or who 
are ART naïve have a higher prevalence of hypertriglyceridemia, 7 studies were compared 
for which no numerical results are provided and all of them showed that the prevalence of 
hypertriglyceridemia was higher in the ART group.  
 
Hypertension in PLHIV on ART 
We identified 2 systematic reviews (35),(42) which report on the prevalence of hypertension 
in PLHIV on ART including a total of 43 cross-sectional studies. Hypertension in these 
systematic reviews is defined as a diagnosis based on raised blood pressures of ≥ 140/90 
mmHg; systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or 
known hypertension as self-reported use of antihypertensive by the patient or from the 
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medical records. Blood pressure ≥ 130/85 mmHg in a known hypertensive was also a 
criterion for confirming the diagnosis of hypertension.  
Of the systematic reviews, Nguyen et al (35) found that the prevalence of hypertension in 
high income countries ranged from 4.7 to 54.4% while that of LMICs ranged from 8.7 to 
45.9%. It was highest in USA (21.2-54.4%) and lowest in Africa (8.7-45.9%). There was no 
statistically significant difference found in the prevalence of hypertension between ART 
exposed and ART naïve groups, however, this was partly attributed to the differences in 
duration of ART use and thus they report that the class of ART used may play a role in 
progression to hypertension in these patients.  
Xu et al (42) reported that prevalence of hypertension in PLHIV ranged between 4.0% to 
67.0%. The global prevalence of hypertension in PLHIV was found to be 25.2% and more so 
higher with increasing age (40.3% ≥ 50 years of age). However, they noted that the 
prevalence in PLHIV on ART was 34.7% while that of those who were ART naïve was 
12.7%. This systematic review included 36 cross-sectional studies which are all part of Table 
3.Naidu et al (34) also assessed the prevalence of hypertension as part of MS and reported a 
mean prevalence of 32.3% amongst all the cross-sectional studies. The mean prevalence’s for 
South America, Asia and Africa has been reported as 35.2%, 24.8% and 21.6% respectively. 
This systematic review also highlights that the prevalence of hypertension in PLHIV on ART 
is higher than that of ART naïve, however, they did not provide any percentages for the said 
groups.  
 
Discussion  
Summary of main results 
In our overview we identified 7 completed systematic reviews from 2009 to date. The last 
search conducted for primary studies within these systematic reviews was in December 2016. 
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These systematic reviews have included 142 cross-sectional studies conducted on participants 
from around the world with variable methodological quality as none of them addressed all the 
domains on the AMSTAR 2 tool. Of note, despite the fact that the systematic reviews 
included in this overview have been published very close to each other and their search 
strategies have included cross-sectional studies conducted over a long period of time, there is 
a very poor overlap of these cross-sectional studies between the systematic reviews which 
poses a threat to their quality as well as the evidence generated by them as ideally the most 
recent systematic review would include all previous primary studies unless a similar 
systematic review was done a decade ago which included the older primary studies hence the 
recent one would consolidate the more recent ones. Only one systematic review (34) assessed 
the prevalence of MS and reported a high mean prevalence of 30.5% of MS in Africa 
followed by Asia and South America.   
The prevalence of depression, MDD and depressive symptoms ranged from as low as 3% to 
64% in PLHIV on ART with high prevalence’s occurring in LMICs; primarily the African 
population. The prevalence of type II diabetes mellitus ranged from 7% to 48.6% where the 
mean prevalence was reported to be lowest (18.1%) in Africa and higher prevalence’s were 
noted in people on ART compared to ART naïve patients. The prevalence of dyslipidemia 
ranged from 6.3% to 100%, the lowest mean prevalence was yet again in Africa (32.8%). On 
individual assessments of the lipid profile, both low HDL cholesterol and 
hypertriglyceridemia were found to have lower prevalence’s in the African population 
compared to others and the use of ART was found to be associated with higher prevalence’s. 
The prevalence of hypertension ranged from 4.0% to 67% globally with higher prevalence’s 
of 35.2% in South America and 24.8% in Asia, while the African population exhibited a 
lower prevalence of 21.6%. Patients over 50 years of age have higher prevalence’s compared 
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to younger people and the use of ART is associated with an increased prevalence of 
hypertension in PLHIV. 
How these findings link with existing research/overall completeness and applicability of 
evidence 
Multi-morbidity reported as MS in Naidu et al was reported to have high prevalence in the 
ART group when comparisons were made between those receiving and not receiving ART. 
This is in keeping with the results of Nguyen et al (20).  
Depression in this overview of systematic reviews ranged from 3% to 64% with highest 
prevalence in the African continent. A cross-sectional study conducted in Ethiopia in 2018 
(44) showed a high prevalence of depression (48.6%) in HIV patients who were receiving 
ART’s. Similarly, Rong et al (45) also reports a high prevalence of depression (40.3%) in the 
Chinese population with HIV on ART treatment. These findings point to the fact that 
depression prevails in PLHIV despite being on ART. This may hinder their quality of lives if 
unrecognized or untreated and lead to poor ART adherence. 
The risk of developing type II diabetes mellitus is two to five times more in PLHIV who are 
receiving ART (22) hence increasing its prevalence. Lowest prevalence’s have been reported 
in African compared to other countries. Thus is the case in Cameroon and Malawi where the 
prevalence’s have been reported to be as low as 2% and 4.1% respectively (46)(47). 
Dyslipidemia is highly prevalent in PLHIV. Dave et al have similarly shown a high 
prevalence of dyslipidemia in both ART consuming (85%) and ART naïve patients (90%) 
(48). However, the prevalence of hypertriglyceridemia is seen to be higher among those on 
ART whilst a higher prevalence of low HDL levels is noted in ART naïve patients in this 
overview which was also demonstrated by Dave et al  but these findings are questionable as 
some studies show the opposite results (49). 
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Hypertension is also highly prevalent in PLHIV which is in keeping with Dimala et al (50) 
(38% had hypertension on ART and 19% in the ART naïve groups) and Nduka et al (51) 
(14.5% vs 10.5% in ART and ART naïve groups respectively). Follow-up study showed that 
the baseline prevalence in HIV patients was 19.3% and 12 months after initiation of ART the 
prevalence increased to 50.2% (50) which demonstrates an increased risk of developing 
hypertension in ART consumers.  
A high burden of multimorbidity which approximates to about 50% was noted in this 
overview which calls for increased surveillance and strengthened models for integrated 
approach to treating and screening PLHIV. Of the many approaches suggested, one is 
strengthening the health workforce through task shifting and capacity building by educating 
the health cadres so that they are competent and patient-focused (14)(18). Pragna et al in their 
systematic review assessed NCDs in low- and middle- income countries where they identified 
barriers to NCD care which include poor infrastructure, interrupted supply of NCD 
medications, inadequate diagnostics, lack of NCD specialists and general health care workers 
etc.(52). This poses a threat to sustaining HIV-NCD integrated care and needs to be focused 
on in order to assess the outcomes of integration and be able to cost effectively provide 
service to PLHIV(17). 
 
Strengths and Limitations 
We have a strong search methodology as we conducted a comprehensive search in 7 
databases, 2 reviewers performed screening independently and data extraction was done by 
one author which was checked by the second author. Our results are not restricted to any 
continent or population and we have assimilated all the prevalence’s to provide a range of 
values for the global prevalence’s of NCD’s as reported in the cross-sectional studies 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
included in the systematic reviews. We conducted our search in February 2018 and of the 
included systematic reviews the latest one conducted their search in December 2016. Hence, 
this overview does not include any cross-sectional studies published thereafter i.e. in 
2017/2018. Also, cross-sectional studies which were not included in any of our included 
systematic reviews are not part of this overview. 
This is the first overview conducted on the said topic and it includes 7 systematic reviews. It 
can be used to serve as a base from which further improved systematic reviews can be 
conducted as we observed gaps in the conduct of systematic reviews which needs to be 
addressed to authors who are going to embark on conducting systematic reviews in the future. 
It can also be used to inform policies and practices. We did not extract prevalence data from 
the individual cross-sectional studies and adherence to ART treatment is unknown.  We only 
used some of the AMSTAR 2 tool domains to assess methodological quality. This overview 
does not contain any information on the types and duration of ART use by the patients as data 
were not available across all the systematic reviews and importantly it highlights that 
multimorbidity has been scarcely researched on as we only have one systematic review 
assessing its prevalence in PLHIV 
 
Conclusions 
Implications for practice 
The high burden of NCD’s in PLHIV calls for dedicated efforts to identify those with NCD’s 
early through screening programs and to implement comprehensive treatment for those 
diagnosed.   
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Implications for research 
Primary/cross-sectional studies need to be conducted which focus on assessing prevalence of 
multimorbidity with NCD’s instead of focusing on one NCD. Complete information should 
be provided by investigators on adherence, duration and type of ART received by 
participants. Furthermore, authors conducting systematic reviews need to follow the PRISMA 
reporting guidelines.  
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Table 3: Mapping of Cross-sectional studies included in the completed systematic reviews 
N
o.  
Study ID Sam
ple 
size 
Country  AR
T 
stat
us ( 
% )  
Dysli
p-
idem
ia 
Hype
r-
tensi
on  
Diab
e-tes  
Depr
es-
sion  
N
ai
d
u
 2
0
1
7
 
P
ri
o
re
sc
h
i 
2
0
1
7
 
B
ra
n
d
t 
2
0
0
9
 
X
U
 2
0
1
7
 
N
g
u
y
en
 2
0
1
5
 
L
o
w
th
er
 2
0
1
4
 
B
er
n
ar
d
 2
0
1
7
 
1 
Adewuya 
2008 
87 Nigeria 100    √      X X 
2 
Adewuya 
2009 
190 Nigeria 100        √           X  
3 
Alciati 
2001 
90 Italy  
95.
5  
      √           X   
4 
Alemu 
2012 
1722 Ethiopia 100       √             X 
5 
Alencastr
o 2012  
1240 Brazil 
65.
7  
√ √ √   X             
6 
Ammass
ari 2004 
135 Italy  100        √           X   
7 
Antonell
o 2015 
1009 Brazil 73     √           X       
8 
Asangbe
h 2015 
200 
Camero
on 
100       √             X 
9 
Awotedu 
2010 
86 
South 
Africa  
100 √ √ √   X             
10 
Bajaj 
2013 
70 India 67  √ √ √   X             
11 
Balderso
n 2013 
452 
United 
States  
100    √             X     
12 
Bayon 
2012 
799 Spain 100        √           X   
13 
Begovac 
2015 
254 Serbia 100   √           X       
14 
Belenky 
2014 
403 
Tanzani
a  
100        √             X 
15 
Berhane 
2012 
313 Ethiopia 100 √  √ √   X       X     
16 
Berhe 
2013 
269 Ethiopia 100        √             X 
17 
Bernardi
no 2011 
310 Spain 71   √             X     
18 
Besa 
2015 
185 Zambia 
98.
4 
      √             X 
19 
Bhat 
2013 
299 India 100       √           X   
20 
Bhengu 
2011 
149 
South 
Africa 
100       √           X   
21 
Bongong
o 2013 
117 
South 
Africa 
100       √           X X 
22 
Bonjoch 
2014 
970 Spain 100    √           X       
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23 
Braganca 
2011 
130 Portugal 100       √           X   
24 
Broom 
2012 
180 
Australi
a  
88   √             X     
25 
Bryant 
2015 
79 
United 
States  
100   √           X       
26 
Buathong 
2009 
379 Thailand 100       √           X   
27 
Buchacz 
2013 
3166 
United 
States  
100   √           X       
28 
Cahn 
2010 
3966 
Multisite
*  
100 √ √ √   X             
29 
Calza 
2014 
894 Italy  
77.
5 
  √           X       
30 Cha 2008 215 
United 
States  
100       √           X   
31 
Chan 
2013 
733 
Australi
a  
83   √             X     
32 Chu 2011 854 
United 
States  
76   √             X     
33 
Cianflon
e 2011 
223 
United 
States  
83   √           X       
34 
Clarke 
2010 
50 Jamaica 79       √           X   
35 De 2012 94 India 100        √           X   
36 
De Socio 
2014 
1182 Italy  94   √             X     
37 
De souza 
2011 
1245 Brazil 100       √           X   
38 
Diaz 
2016 
2960 Brazil 100   √           X       
39 
Dimala 
2016 
100  
Camero
on 
100    √           X       
40 
Dimodi 
et al 
2014 
463 
Camero
on 
75.
2 
√ √ √   X             
41 
Diouf 
2012 
242 Senegal 100   √           X X     
                                        
42  
Divala 
2016 
952 Malawi 
95.
9 
  √           X       
43 Do 2010 300 
Botswan
a 
81.
3 
      √           X X 
44 Do 2013 615 Vietnam 100       √           X   
45 
Fabbiani 
2013 
245 Italy 
93.
9 
  √           X X     
46 
Farley 
2010 
399 Nigeria 40       √             X 
47 
Farrant 
2012 
385 
South 
Africa 
98.
4 
      √           X   
48 
Freeman 
2007/8 
900 
South 
Africa 
18       √     X         
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49 
Galli 
2012 
2345 Italy  
91.
5 
  √           X       
50 
Garvie 
2011 
12 
United 
States  
45       √           X   
51 
Gaynes 
2012 
400 
Camero
on 
100       √           X X 
52 
Gibbie 
2006 
78 
Australi
a  
94       √           X   
53 
Gonzalez 
2011 
91 
United 
States  
100       √           X   
54 
Gordillo 
1999 
366 Spain 100       √           X   
55 
Hejazi 
2012 
340 
Malaysi
a 
100   √             X     
56 
Idiculla 
2011 
60 India  50  √ √ √   X             
57 
Ikeda 
2013 
1240 Brazil  
65.
7 
  √           X       
58 
Isasti 
2013 
196 Spain 
94.
4 
  √           X       
59 
Iwuala 
2015 
145 Nigeria 100   √           X       
60 
Janiszew
ski 2011 
2322 Italy  100   √             X     
61 
Jantarapa
kde 2014 
580 Thailand 71 √ √ √   X             
62 
Judd 
2005 
129 
Australi
a  
93       √           X   
63 
Julius 
2009 
304 
South 
Africa 
100  √ √ √   X       X     
64 
Kagaruki 
2014 
671 
Tanzani
a 
52.
8 
   √ √     X     X     
65 
Kagee 
2010 
85 
South 
Africa  
60       √             X 
66 
Kagee 
2013 
200 
South 
Africa   
100       √             X 
67 
Karambe 
2010 
286 Mali 50       √             X 
68 
Keltner 
2012 
397 
United 
States  
75       √           X   
69 
Kitshoff 
2012 
146 
South 
Africa 
100       √             X 
70 
Knowlto
n 2011 
154 
United 
States  
83         √           X   
71 
Kong 
2012 
7034 
United 
States  
100       √           X   
72 
L'akoa 
2013 
100 
Camero
on 
67       √             X 
73 
Lawler 
2011 
120 
Botswan
a  
97.
5  
      √           X X 
74 
Maganga 
2015 
301 
Tanzani
a 
50.
2   
    √     X           
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75 Maj 1994 408 
Zaire, 
Kenya 
47.
3 
      √     X         
76 
Malangu 
2014 
190 
Botswan
a  
100 √ √ √   X             
77 
Manuthu 
2008 
295 Kenya 45     √ √     X     X     
78 
Martin 
2014 
263 Uganda 100        √             X 
79 
Martinez 
2008 
421 Uganda 57       √             X 
80 
Mbunkah 
2014 
173 
Camero
on 
50 v √ √   X             
81 
Medina-
Torne 
2012 
707 
United 
States 
72   √           X X     
82 
Menezes 
2011 
213 Brazil 100   √           X       
83 
Michel 
2010 
328 France 91        √           X   
84 
Mital 
2013 
200 India  50 √ √ √   X             
85 
Mohamm
ed 2015 
393 Ethiopia 
72.
3 
  √ √     X   X       
86 
Monteiro 
2012 
261 Brazil  89   √           X       
87 
Muronya 
2011 
174 Malawi 100   √           X X     
88 
Myer 
2008 
465 
South 
Africa 
48        √     X       X 
89 
Myerson 
2014 
4278 
United 
States 
87.
5 
  √           X X     
90 
Nakimuli
-Mpungu 
2011 
500 Uganda 100       √           X 
 
X 
91 
Nakimuli
-Mpungu 
2013 
400 Uganda 
 
100  
      √           X X 
92 
Nakku 
2013 
618 Uganda 
64.
6 
      √             X 
93 
Negash 
2013 
355 Ethiopia 100       √             X 
94 Nel 2013 96 
South 
Africa 
100        √           X X 
95 
Nery 
2013 
294 Brazil 
66.
3 
  √           X       
96 
Ngo 
2013 
40 Uganda 100       √             X 
97 
Nozaki 
2011 
518 Zambia 100       √           X   
98 
Nsagha 
2015 
215 
Camero
on 
74.
4 
 √  √      X   X       
99 
Nyamath
i 2013  
68 India 100        √           X   
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10
0 
Ogunmol
a 2014 
250 Nigeria 
32.
2 
  √           X       
10
1 
Olalla 
2013 
388 Spain 
86.
1 
  √           X       
10
2 
Olisah 
2010 
310 Nigeria 100       √           X X 
10
3 
Overton 
2012 
670 
United 
States  
79   √           X       
10
4 
Owolabi 
2012 
300 Nigeria 92        √           X   
10
5 
Pacheco 
2015 
591 Brazil  89    √           X       
10
6 
Palmer 
2011 
451 Canada 100        √           X   
10
7 
Pappin 
2012 
716 
South 
Africa 
100       √           X X 
10
8 
Parikh 
2015 
150 
United 
States  
100   √           X       
10
9 
Patel 
2013 
454 
United 
States  
82   √           X       
11
0 
Peck 
2014 
301 
Tanzani
a  
50.
2  
  √           X       
11
1 
Peretti-
Watel 
2006 
2932 France 53       √           X   
11
2 
Peterson 
2012 
252 Gambia 100       √           X   
11
3 
Poupard 
2007 
200 Senegal 100        √     X     X X 
11
4 
Pumpradi
t 2010 
64 Thailand 100        √           X   
          
11
5 
Rabkin 
2000 
133  
United 
States  
84-
91#  
      √           X   
11
6 
Reinsch 
2012 
803 
German
y 
85.
4 
  √           X X     
11
7 
Roux 
2009 
1809 France 100       √           X   
11
8 
Sarna 
2008 
310 India 100       √           X   
11
9 
Schoesso
n 2007 
193 Sweden 100        √           X   
12
0 
Seth 
2014 
3538 
Kenya, 
Namibia
, 
Tanzani
a 
64       √             X 
12
1 
Sherer 
2014 
2035 Global 100   √             X     
12
2 
Signorini 
2012 
819 Brazil 76 √ √ √   X             
12
3 
Silva 
2009 
215 Brazil 100  √ √ √   X             
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12
4 
Silveria 
2012 
246 Brazil 100       √           X   
12
5 
Simbayi 
2007 
1063 
South 
Africa 
50       √     X       X 
12
6 
Simoni 
2007 
136 
United 
States  
89.
7  
      √           X   
12
7 
Starace 
2002 
268 Italy  
66.
7  
      √           X   
12
8 
Sulyok 
2015 
136 Hungary 92   √           X       
12
9 
Sumari-
de Boer 
2012 
201 
Netherla
nds 
100       √           X   
13
0 
Tesfaye 
2014 
374 Ethiopia 
50.
3 
√ √ √   X X           
13
1 
Tongma 
2013 
111 
United 
States  
100   √           X       
13
2 
Villamar 
2011 
114 Ecuador 
88.
5 
√ √ √   X             
13
3 
Viskovic 
2013 
110 Croatia 100   √           X       
13
4 
Werberic
h 2013 
184 Brazil 100 √ √ √   X             
13
5 
Wolfe 
2006 
112 
Botswan
a  
100       √           X   
13
6 
Wolitski 
2009 
637 
United 
States  
97       √           X   
13
7 
Wouters 
2012 
716 
South 
Africa 
100        √           X X 
13
8 
Wroe 
2015 
292 Rwanda 100       √             X 
13
9 
Wu 2014 920 Taiwan 
> 
95 
  √           X X     
14
0 
Yeji 
2014 
272 
South 
Africa 
100       √             X 
14
1 
Yen 2004 41 China  100       √           X   
14
2 
Zhang 
2012 
563 Canada 100       √           X   
 
 
 
 
  
*Argentina, Brazil, Colombia, Ecuador, Peru, Venezuela 
#ART 84% of the 75 men and 91% of the 58 women 
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Table 4: Table of Excluded systematic reviews  
Study ID Reason for exclusion  
Alessandra 2016 (53), Alexandra 2016 (54), 
Amir 2017 (55), Dillon 2013 (53), Dimala 2017 
(54), Echecopar-Sabogal 2017 (55), Nduka 2016 
(41), Nduka 2017 (56), Piliero 2003 (57) 
 
Assessed association between NCDs and HIV 
and not prevalence of NCD in HIV patients 
Angkurawaranon 2016 (56) Had separate groups of HIV/ART/Hypertension 
that were matched 
Balt 2013 (57), Brown 2008 (58), Lo 2011 (59), 
McKeage 2009 (60), Watkins 2011 (61), 
Watkins 2016 (62), Willig 2016 (63) 
Not a cross-sectional study design 
Dube 2000 (64), Polo 2006 (65) Clinical guideline  
Nguyen 2016 (20) Assessed the prevalence of metabolic syndrome 
but did not report on its individual components 
Bongani 2017 (66), Casaretti 2011 (67), 
Chidozie 2014 (68), D'Ascenzo 2012 (69), Ena 
2003 (70), Green 2002 (71), Langebeek 2014 
(72), Maurice 2017 (73), Mayston 2012 (74), 
Melroe 1999 (75), Memiah 2014 (75), Nduka 
2015 (76), Pantelic 2015 (77), Reust 2011 (78), 
Rueda 2016 (79), Samson 2017 (80), Swenson 
2006 (81), Tao 2017 (82), Tsai 2014 (83), 
Unachukwu 2009 (84), Uthman 2014 (85), Yuen 
2016 (86) 
 
Did not the assess outcomes that we are 
interested in 
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Additional files 
Additional file 1: Search strategy  
Search Output from MEDLINE (via PubMed) 
No date limitations 
Search date: 27 Feb 2018 
Results: 158 
No. Query Items found 
#15 #12 OR #14 158 
#14 Search #3 AND #10 Sort by: Best Match Filters: Systematic Reviews; Meta-Analysis 346 
#13 Search #3 AND #10 4529 
#12 Search #3 AND #10 AND #11 35 
#11 Search (((("systematic review") OR (("meta-analysis" OR "meta analysis")))[title/abstract] OR 
sysrev_methods [sb]) OR "Meta-Analysis"[Publication Type]) 
100043 
#10 Search #4 OR #5 OR #6 OR #7 OR #8 OR #9 1361077 
#9 Search (((((depression OR depressive)))[title/abstract] OR "Depression"[Mesh]) OR "Depressive 
Disorder"[Mesh]) 
187994 
#8 Search ((((dyslipidaemia OR dyslipidemia OR cholesterol OR LDL OR HDL OR triglyceride OR 
triglycerides OR low density lipoprotein OR high density lipoprotein OR low-density lipoprotein OR high-
density lipoprotein)))[title/abstract] OR "Dyslipidemias"[Mesh]) 
73403 
#7 Search ("Hypertension"[Mesh] OR (hypertension OR "blood pressure")) 726226 
#6 Search ((((diabetes OR "diabetes mellitus")))[title/abstract] OR "Diabetes Mellitus"[Mesh]) 377084 
#5 Search ("noncommunicable disease" OR "noncommunicable diseases" OR "non-communicable disease" OR 
"non-communicable diseases" OR NCD OR NCDs OR "Noncommunicable Diseases"[Mesh]) 
10613 
#4 Search (((((comorbidity OR co-morbidity OR "co morbidity" OR multimorbidity OR multi-morbidity OR 
"multi morbidity")))[title/abstract] OR "Multimorbidity"[Mesh]) OR "Comorbidity"[Mesh]) 
91585 
#3 #1 AND #2 113375 
#2 Search ((((antiretroviral agents [Mesh] OR antiretroviral therapy, highly active [Mesh]))) OR 
((Antiretroviral* OR ((anti) AND (retroviral*)) OR ARV* OR ART OR "antiretroviral therapy" OR HAART 
OR ((highly) AND (active) AND (antiretroviral*) AND (therap*)) OR ((anti) AND (hiv)) OR ((anti) AND 
(acquired immunodeficiency)) OR ((anti) AND (acquired immuno-deficiency)) OR ((anti) AND (acquired 
immune-deficiency)) OR ((anti) AND (acquired immun*) AND (deficienc*))))) 
235672 
#1 Search (((((HIV OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human immunodeficiency virus 
OR human immune deficiency virus OR human immuno-deficiency virus OR human immune-deficiency 
virus OR ((human immun*) AND (deficiency virus)) OR acquired immunodeficiency syndromes OR 
acquired immune deficiency syndrome OR acquired immuno-deficiency syndrome OR acquired immune-
deficiency syndrome OR ((acquired immun*) AND (deficiency syndrome)) OR HIV/AIDS)))) OR ((HIV 
infections [MeSH] OR HIV [MeSH]))) 
389357 
 
Search Output from Cochrane Database of Systematic Reviews (CDSR) 
No date limitations 
Search date: 27 Feb 2018 
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Results: 966 
1 HIV or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human immunodeficiency virus 
or human immune deficiency virus or human immuno-deficiency virus or human 
immune-deficiency virus 
19064 
2 ((human immun*) and (deficiency virus)) or acquired immunodeficiency syndromes or 
acquired immune deficiency syndrome or acquired immuno-deficiency syndrome or 
acquired immune-deficiency syndrome 
2008 
3 ((acquired immun*) and (deficiency syndrome)) 1350 
4 HIVAIDS 4 
5 MeSH descriptor: [HIV Infections] explode all trees 9825 
6 MeSH descriptor: [HIV] explode all trees 3036 
7 #1 or #2 or #3 or #4 or #5 or #6 19497 
8 MeSH descriptor: [Anti-Retroviral Agents] explode all trees 4195 
9 MeSH descriptor: [Antiretroviral Therapy, Highly Active] explode all trees 1289 
10 antiretroviral* 6098 
11 anti and retroviral* 847 
12 ARV* or ART or "antiretroviral therapy" or HAART 96034 
13 highly and active and antiretroviral* and therap* 2121 
14 anti and hiv 5237 
15 anti and "acquired immunodeficiency" 477 
16 anti and "acquired immuno-deficiency" 58 
17 anti and "acquired immune-deficiency" 682 
18 anti and "acquired immun*" and deficienc* 713 
19 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 99271 
20 #7 and #19 10776 
21 MeSH descriptor: [Comorbidity] explode all trees 3564 
22 MeSH descriptor: [Multimorbidity] explode all trees 4 
23 comorbidity or co-morbidity or "co morbidity" or multimorbidity or multi-morbidity or 
"multi morbidity" 
11571 
24 #21 or #22 or #23 11571 
25 MeSH descriptor: [Noncommunicable Diseases] explode all trees 0 
26 "noncommunicable disease" or "noncommunicable diseases" or "non-communicable 
disease" or "non-communicable diseases" or NCD or NCDs 
402 
27 #25 or #26 402 
28 MeSH descriptor: [Diabetes Mellitus] explode all trees 21495 
29 diabetes or "diabetes mellitus" 52709 
30 #28 or #29 54092 
31 hypertension or "blood pressure" 89630 
32 MeSH descriptor: [Hypertension] explode all trees 15899 
33 #31 or #32 89630 
34 dyslipidaemia or dyslipidemia or cholesterol or LDL or HDL or triglyceride or 
triglycerides or "low density lipoprotein" or "high density lipoprotein" or "low-density 
lipoprotein" or "high-density lipoprotein" 
34845 
35 MeSH descriptor: [Dyslipidemias] explode all trees 5785 
36 #34 or #35 35557 
37 depression or depressive 55189 
38 MeSH descriptor: [Depressive Disorder] explode all trees 9229 
39 MeSH descriptor: [Depression] explode all trees 7658 
40 #37 or #38 or #39 55229 
41 #24 or #27 or #30 or #33 or #36 or #40 204541 
42 #20 AND #41 2117 
43 #42 in Cochrane Reviews (Reviews and Protocols) 966 
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Search Output from Database of Abstracts of Reviews of Effects (DARE) 
No date limitations; but DARE has only been updated until 2015: Issue 2 of 4, April 2015 
Search date: 27 Feb 2018 
Results: 121 
1 HIV or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human immunodeficiency 
virus or human immune deficiency virus or human immuno-deficiency virus or human 
immune-deficiency virus 
19064 
2 ((human immun*) and (deficiency virus)) or acquired immunodeficiency syndromes 
or acquired immune deficiency syndrome or acquired immuno-deficiency syndrome or 
acquired immune-deficiency syndrome 
2008 
3 ((acquired immun*) and (deficiency syndrome)) 1350 
4 HIVAIDS 4 
5 MeSH descriptor: [HIV Infections] explode all trees 9825 
6 MeSH descriptor: [HIV] explode all trees 3036 
7 #1 or #2 or #3 or #4 or #5 or #6 19497 
8 MeSH descriptor: [Anti-Retroviral Agents] explode all trees 4195 
9 MeSH descriptor: [Antiretroviral Therapy, Highly Active] explode all trees 1289 
10 antiretroviral* 6098 
11 anti and retroviral* 847 
12 ARV* or ART or "antiretroviral therapy" or HAART 96034 
13 highly and active and antiretroviral* and therap* 2121 
14 anti and hiv 5237 
15 anti and "acquired immunodeficiency" 477 
16 anti and "acquired immuno-deficiency" 58 
17 anti and "acquired immune-deficiency" 682 
18 anti and "acquired immun*" and deficienc* 713 
19 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 99271 
20 #7 and #19 10776 
21 MeSH descriptor: [Comorbidity] explode all trees 3564 
22 MeSH descriptor: [Multimorbidity] explode all trees 4 
23 comorbidity or co-morbidity or "co morbidity" or multimorbidity or multi-morbidity 
or "multi morbidity" 
11571 
24 #21 or #22 or #23 11571 
25 MeSH descriptor: [Noncommunicable Diseases] explode all trees 0 
26 "noncommunicable disease" or "noncommunicable diseases" or "non-communicable 
disease" or "non-communicable diseases" or NCD or NCDs 
402 
27 #25 or #26 402 
28 MeSH descriptor: [Diabetes Mellitus] explode all trees 21495 
29 diabetes or "diabetes mellitus" 52709 
30 #28 or #29 54092 
31 hypertension or "blood pressure" 89630 
32 MeSH descriptor: [Hypertension] explode all trees 15899 
33 #31 or #32 89630 
34 dyslipidaemia or dyslipidemia or cholesterol or LDL or HDL or triglyceride or 
triglycerides or "low density lipoprotein" or "high density lipoprotein" or "low-density 
lipoprotein" or "high-density lipoprotein" 
34845 
35 MeSH descriptor: [Dyslipidemias] explode all trees 5785 
36 #34 or #35 35557 
37 depression or depressive 55189 
38 MeSH descriptor: [Depressive Disorder] explode all trees 9229 
39 MeSH descriptor: [Depression] explode all trees 7658 
40 #37 or #38 or #39 55229 
41 #24 or #27 or #30 or #33 or #36 or #40 204541 
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42 #20 AND #41 2117 
43 #42 in Other Reviews 121 
 
 
Search Output from CINAHL (EBSCOHost) 
 
Search date: 27 Feb 2018 
No date limits 
Results: 49 
Search 
Terms Search Options 
S46 S21 AND S41 AND S45 View Results (49) 
S45 S42 OR S43 OR S44  View Results (70,001) 
S44 MH systematic review  View Results (36,541) 
S43 AB "systematic review" OR meta-analysis  View Results (28,494) 
S42 PT "systematic review" OR meta-analysis  View Results (50,859) 
S41 S24 OR S25 OR S28 OR S31 OR S35 OR S38 View Results (247,959) 
S38 S36 OR S37 View Results (77,053) 
S37 MH depression  View Results (54,589) 
S36 AB depression or "depressive disorder"  View Results (48,547) 
S35 S32 OR S33 OR S34 View Results (24,701) 
S34 MH hyperlipidemia  View Results (6, 
S33 AB hyperlipidemia  View Results (1,705 
S32 AB dyslipidaemia or dyslipidemia or cholesterol or LDL or HDL or 
triglyceride or triglycerides or "low density lipoprotein" or "high density 
lipoprotein" or "low-density lipoprotein" or "high-density lipoprotein"  
View Results (19,813) 
S31 S29 OR S30 View Results (63,161) 
S30 MH hypertension  View Results (29,138) 
S29 AB hypertension OR "blood pressure"  View Results (47,216) 
S28 S26 OR S27 View Results (80,493) 
S27 MH diabetes mellitus  View Results (35,297) 
S26 AB diabetes OR "diabetes mellitus"  View Results (58,542) 
S25 TX "noncommunicable disease" or "noncommunicable diseases" or 
"non-communicable disease" or "non-communicable diseases" or NCD 
or NCDs  
View Results (1,923) 
S24 S22 OR S23 View Results (44,832) 
S23 MH comorbidity  View Results (29,459) 
S22 TX comorbidity or co-morbidity or "co morbidity" or multimorbidity or 
multi-morbidity or "multi morbidity"  
View Results (44,832) 
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S21 S7 AND S20 View Results (15,713) 
S20 S17 OR S18 OR S19 View Results (47,940) 
S19 MH Anti-Retroviral Agents  View Results (1,857) 
S18 MH Antiretroviral Therapy, Highly Active  View Results (2,991) 
S17 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16  View Results (47,940) 
S16 TX anti and "acquired immun*" and deficienc*  View Results (115) 
S15 TX anti and "acquired immune-deficiency"  View Results (74) 
S14 TX anti and "acquired immuno-deficiency"  View Results (2) 
S13 TX anti and "acquired immunodeficiency"  View Results (919) 
S12 TX anti and hiv  View Results (11,134) 
S11 TX highly and active and antiretroviral* and therap*  View Results (3,883) 
S10 TX ARV* or ART or "antiretroviral therapy" or HAART  View Results (40,232) 
S9 TX anti and retroviral*  View Results (2,193) 
S8 TX antiretroviral*  View Results (9,282) 
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6  View Results (77,216) 
S6 MH Human Immunodeficiency Virus  View Results (2,839) 
S5 MH HIV infections  View Results (38,900) 
View Details 
Edit 
S4 TX HIVAIDS  View Results (16) 
S3 TX ((acquired immun*) and (deficiency syndrome))  View Results (711) 
S2 TX ((human immun*) and (deficiency virus)) or acquired 
immunodeficiency syndromes or acquired immune deficiency syndrome 
or acquired immuno-deficiency syndrome or acquired immune-
deficiency syndrome  
View Results (13,885) 
S1 TX HIV or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human 
immunodeficiency virus or human immune deficiency virus or human 
immuno-deficiency virus or human immune-deficiency virus  
View Results (71,286) 
 
 
Search Output from Web of Science – Core Collection 
 
Search date: 27 Feb 2018 
 
No date limits (1970 to present) 
 
Results: 152 
# 17 152 #16 AND #15 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
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# 16 237,822 TOPIC: ((systematic review) OR meta-analysis) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 15 5,667 #14 AND #5 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 14 1,649,568 #13 OR #12 OR #9 OR #8 OR #7 OR #6 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 13 417,078 TOPIC: (depression OR (depressive disorder)) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 12 352,118 #11 OR #10 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 11 111,774 TOPIC: ((low-density lipoprotein) or (high-density lipoprotein)) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 10 324,619 TOPIC: (cholesterol OR dyslipidemia OR LDL or HDL or triglyceride) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 9 532,145 TOPIC: (hypertension OR "blood pressure") 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 8 477,881 TOPIC: (diabetes OR "diabetes mellitus") 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 7 6,246 TOPIC: (non-communicable disease OR NCD) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 6 68,866 TOPIC: (comorbidity OR multimorbidity) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 5 71,454 #4 AND #3 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 4 738,368 #2 OR #1 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
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# 3 357,793 TOPIC: (antiretroviral OR ART OR HAART OR "highly active antiretroviral*" OR 
ARV) 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 2 481,320 TOPIC: (AIDS OR HIV/AIDS OR "acquired immunodeficiency") 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
Edit   
 
# 1 351,763 TOPIC: (HIV* OR "HIV infect*" OR "human immunodeficiency virus") 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, IC Timespan=All years 
   
 
 
 
 
 
 
 
 
Search Output from PROSPERO 
Search date: 27 Feb 2018 
No date limits 
Results: 49 
(HIV OR AIDS OR HIV/AIDS OR Human Immunodeficiency Virus OR acquired immunodeficiency 
syndrome) AND (anti-HIV drugs OR antiretroviral OR anti-retroviral OR ART OR ARV OR HAART OR 
highly-active antiretroviral) AND (comorbidity OR co-morbidity OR multimorbidity OR non-communicable 
disease OR noncommunicable disease OR diabetes OR hypertension OR blood pressure OR cholesterol OR 
dyslipidemia OR dyslipidaemia OR hyperlipidaemia OR hyperlipidemia OR LDL OR HDL OR triglycerides 
OR lipoprotein OR depresssion OR depressive disorder) 
 
Search Output from Epistemonikos 
No date limit 
Search date: 27 Feb 2018 
Search results = 105 
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HIV AND antiretroviral AND (comorbidities OR diabetes OR hypertension OR blood pressure OR cholesterol 
OR dyslipidemia OR hyperlipidemia OR depression OR depressive) [Filters: protocol=no, 
classification=systematic-review] 
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Additional File 2: AMSTAR 2 assessment of included reviews 
AMSTAR 2 
Criteria 
Bernard 2017 Brandt 2009 Lowther 
2014 
Naidu 2017 Nguyen 2015 Prioreschi 
2017 
Xu 2017 
Did the 
research 
questions and 
inclusion 
criteria for the 
review include 
the 
components of 
PICO? 
Was the 
research 
question clear? 
 
NOTE: 
Timeframe, 
Intervention 
& comparator 
are not 
applicable to 
cross-
sectional 
studies.  
 
Population is 
HIV+ adults 
in SSA and 
outcomes are 
prevalence 
and factors 
associated 
with 
depression.   
 
 
Population is 
HIV+ adults 
and the 
outcome is 
mental 
health.  
 
 
 
 
  
 
 
 
Population is 
HIV+ adults 
and 
outcomes are 
the 
prevalence of 
depression, 
anxiety or the 
experience of 
stigma in 
HIV infected 
persons on 
antiretroviral 
therapy.  
Population is 
HIV+ adults 
in developing 
countries and 
the outcomes 
are 
prevalence of 
Metabolic 
syndrome & 
its 
components. 
Population is 
HIV+ and 
Outcomes 
are Burden, 
Determinants 
and 
Pharmacolog
ical 
Management 
of 
Hypertension
.  
 
 
 
 
  
Population is 
PLHIV and 
Outcome is 
development 
of type II 
diabetes 
mellitus. 
Population is 
over 16yr 
PLHIV, 
Outcome is 
prevalence of 
Hypertension 
globally 
Did the report 
of the review 
contain an 
explicit 
statement that 
the review 
methods were 
established 
prior to the 
conduct of the 
review and did 
the report 
justify any 
significant 
deviations 
from the 
protocol? 
There is no 
statement 
about 
protocol 
being written 
a priori or 
any 
deviations 
made from 
the protocol. 
Also, the 
PRISMA 
checklist 
shows NO 
protocol 
registration 
number. 
 
There is no 
statement 
about 
protocol 
being written 
a priori and 
any 
revisions/dev
iations from 
protocol. 
There is no 
statement 
about 
protocol 
being written 
a priori and 
any 
revisions/dev
iations from 
protocol. No 
supplementar
y documents 
are attached.  
There is no 
statement 
about 
protocol 
being written 
a priori and 
any 
revisions/dev
iations from 
protocol, 
methods say 
review done 
in 
accordance 
with 
PRISMA 
guidelines 
but no 
supplementar
y document 
to support 
this. 
 
Protocol 
developed 
with research 
question, 
search 
strategy, 
inclusion/exc
lusion 
criteria and 
ROB 
assessment 
but it was not 
registered.  
Protocol 
available on 
PROSPERO 
via the 
registration 
number 
provided in 
the review, 
they had 
planned for 
meta analysis 
and assessing 
heterogeneity
. 
Not 
mentioned 
that a 
protocol was 
developed/ 
registered. 
Did the review 
authors use a 
comprehensive 
literature 
More than 2 
databases 
were 
searched, 
More than 2 
databases 
searched, 
reference 
More than 2 
databases 
searched, 
keywords 
More than 2 
databases 
searched, and 
keywords 
Only 
searched in 1 
database 
Searched in 4 
databases, 
key words 
provided, and 
Searched in 2 
databases, 
keywords 
provided, 
Stellenbosch University  https://scholar.sun.ac.za
54 
 
search 
strategy? 
keywords are 
provided, and 
restriction 
was on age 
(which is 
justified by 
inclusion 
criteria). 
 
lists were 
searched, and 
keywords are 
listed. They 
included only 
published 
studies and 
English 
studies. Age 
restrictions 
were also 
applied. 
provided, 
only articles 
in English 
and French 
language 
accepted. 
Reference 
lists were 
also 
searched. 
Grey 
literature and 
expert 
opinion are 
not 
mentioned. 
 
have been 
listed. 
restrictions 
justified. 
restricted to 
English 
articles 
Did the review 
authors 
perform study 
selection in 
duplicate? 
Not 
mentioned 
who, and 
how many 
people did 
the study 
selection. 
 
Not 
mentioned 
who and how 
many people 
did study 
selection.  
Only 1 
author did 
the selection 
against the 
inclusion and 
exclusion 
criteria. 
When 
unclear, he 
consulted the 
other author. 
 
More than 2 
reviewers 
performed 
study 
selection.  
   
Not 
mentioned 
who and how 
many people 
did study 
selection. 
2 reviewers 
screened the 
titles and 
abstracts and 
consensus 
was reached 
by 
discussion. 
Not 
mentioned; 
Under author 
contributions 
only one 
author 
seems to 
have done 
study 
selection. 
Did the review 
authors 
perform data 
extraction in 
duplicate? 
Not 
mentioned 
who, and 
how many 
people 
performed 
data 
extraction. 
 
Not 
mentioned 
who and how 
many people 
performed 
data 
extraction. 
 
Not clear. 
Not 
mentioned 
who and how 
many people 
performed 
data 
extraction. 
They have 
stated only 
stated that 
they had a 
form onto 
which data 
was 
extracted. 
Not 
mentioned 
clearly 
whether the 
same people 
who assessed 
eligibility 
also 
extracted 
data. All the 
information 
is 
summarized 
under data 
extraction in 
one 
paragraph. 
 
Not 
mentioned 
who and how 
many people 
performed 
data 
extraction. 
 
2 reviewers 
were 
involved in 
DE and 
based on 
AMSTAR 
"at least two 
reviewers 
achieved 
consensus on 
which data to 
extract from 
included 
studies. 
Prioreschi - 
One reviewer 
(AP) 
reassessed 
data 
extraction for 
all eligible 
full texts. 
Standardized 
forms were 
used to 
extract data. 
Two authors 
extracted 
data and 
upon 
differences 
consensus 
was by 
discussion 
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Did the review 
authors 
provide a list 
of excluded 
studies and 
justify the 
exclusions? 
They have 
not listed 
excluded 
studies even 
in the 
supplementar
y documents. 
 
They have 
not listed 
excluded 
studies. 
They have 
not listed 
excluded 
studies. 
They have 
not listed 
excluded 
studies. 
They have 
not listed 
excluded 
studies. 
They have 
not listed 
excluded 
studies. 
They have 
not listed 
excluded 
studies. 
Did the review 
authors 
describe the 
included 
studies in 
adequate 
detail?  
 
NOTE: 
Timeframe, 
Intervention 
& comparator 
are not 
applicable to 
cross-
sectional 
studies. 
Population 
(age, HIV 
and ART 
status), 
Outcome 
(prevalence 
of 
depression/de
pressive 
symptoms) 
and type of 
study well 
are well 
described. 
Population 
and study 
parameters 
are well 
described but 
outcome is 
mentioned 
insufficiently 
Not well 
described in 
the tables. 
Made an 
effort. 
Population is 
detailed, 
Outcomes 
are described 
as 
prevalence’s 
of MS and its 
components, 
And the 
study design 
is mentioned 
on the 
heading of 
tables. 
 
Population, 
outcome and 
study setting 
are all 
described in 
adequate 
detail. 
Population, 
outcome and 
study setting 
are all 
described in 
adequate 
detail 
Table of 
included 
studies has 
all important 
details on 
PICO 
Did the review 
authors report 
on the sources 
of funding for 
the studies 
included in the 
review? 
Funding 
sources of 
individual 
studies aren't 
reported. 
There is no 
mention of 
any effort to 
look for it. 
 
Funding 
sources of 
individual 
studies aren't 
reported. 
There is no 
mention of 
any effort to 
look for it. 
 
Funding 
sources of 
individual 
studies aren't 
reported. 
There is no 
mention of 
any effort to 
look for it. 
 
Funding 
sources of 
individual 
studies aren't 
reported nor 
efforts to 
look for it are 
mentioned 
Funding 
sources of 
individual 
studies aren't 
reported nor 
efforts to 
look for it are 
mentioned 
Funding 
sources of 
individual 
studies aren't 
reported nor 
efforts to 
look for it are 
mentioned 
Funding 
sources of 
individual 
studies aren't 
reported nor 
efforts to 
look for it are 
mentioned 
Did the review 
authors 
provide a 
satisfactory 
explanation 
for, and 
discussion of, 
any 
heterogeneity 
observed in the 
results of the 
review? 
Heterogeneit
y observed 
was very 
high with I2 
>80% 
between 
studies in 
most forest 
plots and the 
reasons are 
mentioned. 
Narrative 
causes of 
heterogeneity 
were 
explored, no 
statistical 
tests done. 
They 
discussed the 
impact of this 
on the results 
of their 
review.  
 
Sources and 
impact of the 
heterogeneity 
are discussed 
but not in 
detail. 
They 
mention 
reasons of 
heterogeneity 
being 
different 
criteria’s for 
diagnosing 
MS and 
components. 
Also, 
different 
groups (ART 
and ART 
naïve) have 
They 
explained 
possible 
reasons for 
the wide 
range of 
prevalence’s’ 
observed  
Not 
mentioned its 
impact; they 
did expect 
heterogeneity 
and I2 is 
high, but 
reasons not 
explored 
They 
explored 
heterogeneity 
and 
discussed its 
impact 
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been 
included 
from the 
primary 
studies which 
are a cause of 
heterogeneity
. 
 
If they 
performed 
quantitative 
synthesis did 
the review 
authors carry 
out an 
adequate 
investigation 
of publication 
bias (small 
study bias) and 
discuss its 
likely impact 
on the results 
of the review? 
 
Meta-
analysis done 
but no 
mention of 
publication 
bias/ no 
graphical or 
statistical 
illustration. 
 
Meta-
analysis not 
done. No 
mention of 
publication 
bias/ no 
graphical or 
statistical 
illustration.  
Meta-
analysis not 
done. Only 
mentioned 
about a small 
number of 
studies 
reporting a 
particular 
outcome, but 
no graphical 
or statistical 
illustration of 
publication 
bias. 
Meta-
analysis not 
done. No 
mention of 
publication 
bias/ no 
graphical or 
statistical 
illustration. 
Meta-
analysis not 
done. No 
mention of 
publication 
bias/ no 
graphical or 
statistical 
illustration. 
Meta 
analysis has 
been done 
and they 
have 
mentioned 
that few 
studies have 
been 
included 
causing a 
bias but no  
graphical or 
statistical 
tests for 
publication 
bias have 
been done 
and there is 
no discussion 
about the 
likelihood 
and 
magnitude of 
impact of 
publication 
bias  
 
Meta 
analysis has 
been done 
but  
no  
graphical or 
statistical 
tests for 
publication 
bias have 
been done. 
LOOK FOR 
THE 
FOREST 
PLOTS 
FROM 
APPENDIX 
  
Did the review 
authors report 
any potential 
sources of 
conflict of 
interest, 
including any 
funding they 
received for 
conducting the 
review? 
Source of 
funding 
mentioned 
and also 
declared that 
there were no 
conflicts of 
interest. 
 
Source of 
funding is 
mentioned.  
Source of 
funding 
mentioned 
and also 
declared that 
there were no 
conflicts of 
interest. 
Source of 
funding 
mentioned 
and also 
declared no 
competing 
interests 
Sources of 
funding 
mentioned, 
and conflicts 
declared 
Sources of 
funding 
mentioned, 
and conflicts 
declared  
Conflicts 
declared 
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Additional File 3: PRISMA reporting checklist – 2009 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number.  
6 -7 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  11 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
12 
METHODS   
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
n/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
16,17,43 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
18 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
21-23 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
n/a 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
n/a 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  23 
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
11 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
11 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
13 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
44 - 50 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
14 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming data from 
investigators.  
14 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
12 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
15 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  15 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
15 
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Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
n/a 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
28-29 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
31 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
31,32 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
34 
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Appendix 1 
Instructions for authors 
The instructions for authors submitting to the BMC – Systematic Reviews journal have been 
summarized below. The link to this journal is 
https://systematicreviewsjournal.biomedcentral.com/ 
Research articles include any original primary research relating to the design, conduct or 
reporting of systematic reviews, as well as traditional systematic review results papers. 
Systematic Reviews strongly encourages that all datasets on which the conclusions of the 
paper rely should be available to readers deposited on repositories or in main manuscript or 
as additional files. 
There is no word count for the manuscript submitted. Vancouver referencing style should be 
used, font size/type not stated. There is no limitation on the number of tables/figures. If it is 
less than A4 the it should be within the text, if A4 size then at the end. Longer than A4 should 
be provided as supplementary documents. 
Reporting standards - for completed systematic reviews, Systematic Reviews requires the 
submission of a populated PRISMA checklist and flow diagram. The flow diagram should be 
included in the main body of the text and the checklist should be provided as an additional 
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file, both the flow diagram and the checklist should be referenced in the text. Submissions 
received without these elements will be returned to the authors as incomplete. 
 
 
The manuscript should include the following:  
1. The Declarations section including all of the subheadings. 
2. The Title page should: 
• present a title that includes, if appropriate, the study design e.g. for non-clinical or 
non-research studies a description of what the article reports 
• list the full names, institutional addresses and email addresses for all authors 
• indicate the corresponding author 
3. The Abstract should not exceed 350 words. No references should be cited in the abstract 
and abbreviations should be minimized. Reports of systematic reviews should follow the 
PRISMA extension for abstracts. The abstract must include the following sections: 
• Background: the context and purpose of the study 
• Methods: how the study was performed, and statistical tests used 
• Results: the main findings 
• Conclusions: brief summary and potential implications 
• Systematic review registration: if your systematic review is registered in a publicly 
accessible registry, include the name of the registry and registration number.  
4. Three to ten keywords representing the main content of the article. 
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5. The Background section should explain the background to the study, its aims, a summary 
of the existing literature and why this study was necessary or its contribution to the field. 
6. The Methods section should include: 
• the aim, design and setting of the study 
• the characteristics of participants or description of materials 
• a clear description of all processes, interventions and comparisons. Generic drug 
names should generally be used. When proprietary brands are used in research, include the 
brand names in parentheses 
• the type of statistical analysis used, including a power calculation if appropriate. 
7. The Results section - Should include the findings of the study including, if appropriate, 
results of statistical analysis which must be included either in the text or as tables and figures. 
8. Discussion - This section should discuss the implications of the findings in context of 
existing research and highlight limitations of the study. 
9. Conclusions - This should state clearly the main conclusions and provide an explanation of 
the importance and relevance of the study reported. 
10. List of Abbreviations - If abbreviations are used in the text, they should be defined in the 
text at first use, and a list of abbreviations should be provided. 
11. Declarations - All manuscripts must contain the following sections under the heading 
'Declarations': 
• Ethics approval and consent to participate 
• Consent for publication 
• Availability of data and material 
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• Competing interests 
• Funding 
• Authors' contributions 
• Acknowledgements 
• Authors' information (optional) 
NOTE: If any of the sections are not relevant to your manuscript, please include the heading 
and write 'Not applicable' for that section.  
Elaboration of some of the elements from the declaration section: 
a) Availability of data and materials 
All manuscripts must include an ‘Availability of data and materials’ statement. Data 
availability statements should include information on where data supporting the results 
reported in the article can be found including, where applicable, hyperlinks to publicly 
archived datasets analysed or generated during the study.  
Data availability statements can take one of the following forms (or a combination of more 
than one if required for multiple datasets): 
• The datasets generated and/or analysed during the current study are available in the 
[NAME] repository, [PERSISTENT WEB LINK TO DATASETS] 
• The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
• All data generated or analysed during this study are included in this published article 
[and its supplementary information files]. 
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• The datasets generated and/or analysed during the current study are not publicly 
available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the 
corresponding author on reasonable request. 
• Data sharing is not applicable to this article as no datasets were generated or analysed 
during the current study. 
• The data that support the findings of this study are available from [third party name] 
but restrictions apply to the availability of these data, which were used under license for the 
current study, and so are not publicly available. Data are however available from the authors 
upon reasonable request and with permission of [third party name]. 
• Not applicable. If your manuscript does not contain any data, please state 'Not 
applicable' in this section. 
 
BioMed Central also requires that authors cite any publicly available data on which the 
conclusions of the paper rely in the manuscript. Data citations should include a persistent 
identifier (such as a DOI) and should ideally be included in the reference list. Citations of 
datasets, when they appear in the reference list, should include the minimum information 
recommended by DataCite and follow journal style. Dataset identifiers including DOIs 
should be expressed as full URLs. For example: 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring 
and prediction system (GIDMaPS) data sets. figshare. 2014. 
http://dx.doi.org/10.6084/m9.figshare.853801 
b) Competing interests 
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If you do not have any competing interests, please state "The authors declare that they have 
no competing interests" in this section. 
c) Funding 
All sources of funding for the research reported should be declared. The role of the funding 
body in the design of the study and collection, analysis, and interpretation of data and in 
writing the manuscript should be declared. 
d) Authors' contributions 
The individual contributions of authors to the manuscript should be specified in this section.  
Please use initials to refer to each author's contribution in this section, for example: "FC 
analyzed and interpreted the patient data regarding the hematological disease and the 
transplant. RH performed the histological examination of the kidney and was a major 
contributor in writing the manuscript. All authors read and approved the final manuscript." 
e) Acknowledgements 
Please acknowledge anyone who contributed towards the article who does not meet the 
criteria for authorship including anyone who provided professional writing services or 
materials. 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
f) Authors' information 
This section is optional. 
You may choose to use this section to include any relevant information about the author(s) 
that may aid the reader's interpretation of the article, and understand the standpoint of the 
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author(s). This may include details about the authors' qualifications, current positions they 
hold at institutions or societies, or any other relevant background information. Please refer to 
authors using their initials. Note this section should not be used to describe any competing 
interests. 
 
 Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all 
notes (along with their corresponding letter) should be included in the Endnotes section. 
Please format this section in a paragraph rather than a list. 
Web links and URLs: All web links and URLs, including links to the authors' own websites, 
should be given a reference number and included in the reference list rather than within the 
text of the manuscript. They should be provided in full, including both the title of the site and 
the URL, as well as the date the site was accessed, in the following format: The Mouse 
Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 
2013. If an author or group of authors can clearly be associated with a web link, such as for 
weblogs, then they should be included in the reference. 
 
 
General formatting guidelines: 
a) Preparing main manuscript text 
• Use double line spacing 
• Include line and page numbering 
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• Use SI units: Please ensure that all special characters used are embedded in the text, 
otherwise they will be lost during conversion to PDF 
• Do not use page breaks in your manuscript 
b) File formats 
The following word processor file formats are acceptable for the main manuscript document: 
• Microsoft word (DOC, DOCX) 
• Rich text format (RTF) 
• TeX/LaTeX (use BioMed Central's TeX template) 
• Please note: editable files are required for processing in production. If your 
manuscript contains any non-editable files (such as PDFs) you will be required to re-submit 
an editable file when you submit your revised manuscript, or after editorial acceptance in 
case no revision is necessary. 
• Note that figures must be submitted as separate image files, not as part of the 
submitted manuscript file. For more information, see Preparing figures below. 
 
c) Preparing figures 
When preparing figures, please follow the formatting instructions below. 
• Figures should be provided as separate files, not embedded in the main manuscript 
file. 
• Each figure of a manuscript should be submitted as a single file that fits on a single 
page in portrait format. 
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• Tables should NOT be submitted as figures but should be included in the main 
manuscript file. 
• Multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a single 
composite file that contains all parts of the figure. 
• Figures should be numbered in the order they are first mentioned in the text, and 
uploaded in this order. 
• Figures should be uploaded in the correct orientation. 
• Figure titles (max 15 words) and legends (max 300 words) should be provided in the 
main manuscript, not in the graphic file. 
• Figure keys should be incorporated into the graphic, not into the legend of the figure. 
• Each figure should be closely cropped to minimize the amount of white space 
surrounding the illustration. Cropping figures improves accuracy when placing the figure in 
combination with other elements when the accepted manuscript is prepared for publication on 
our site. For more information on individual figure file formats, see our detailed instructions. 
• Individual figure files should not exceed 10 MB. If a suitable format is chosen, this 
file size is adequate for extremely high-quality figures. 
Figure file types 
We accept the following file formats for figures: 
• EPS (suitable for diagrams and/or images) 
• PDF (suitable for diagrams and/or images) 
• Microsoft Word (suitable for diagrams and/or images, figures must be a single page) 
• PowerPoint (suitable for diagrams and/or images, figures must be a single page) 
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• PNG (suitable for images) 
Figure size and resolution 
Figures are resized during publication of the final full text and PDF versions to conform to 
the BioMed Central standard dimensions, which are detailed below. 
Figures on the web: 
• width of 600 pixels (standard), 1200 pixels (high resolution). 
Figures in the final PDF version: 
• width of 85 mm for half page width figure 
• width of 170 mm for full page width figure 
• maximum height of 225 mm for figure and legend 
• image resolution of approximately 300 dpi (dots per inch) at the final size 
Figures should be designed such that all information, including text, is legible at these 
dimensions. All lines should be wider than 0.25 point when constrained to standard figure 
widths. All fonts must be embedded. 
d) Preparing tables 
When preparing tables, please follow the formatting instructions below. 
• Tables should be numbered and cited in the text in sequence using Arabic numerals 
(i.e. Table 1, Table 2 etc.). 
• Tables less than one A4 or Letter page in length can be placed in the appropriate 
location within the manuscript. 
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• Tables larger than one A4 or Letter page in length can be placed at the end of the 
document text file. Please cite and indicate where the table should appear at the relevant 
location in the text file so that the table can be added in the correct place during production. 
• Larger datasets, or tables too wide for A4 or Letter landscape page can be uploaded as 
additional files. Please see [below] for more information. 
• Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls 
) or comma separated values (.csv). Please use the standard file extensions. 
• Table titles (max 15 words) should be included above the table, and legends (max 300 
words) should be included underneath the table. 
• Tables should not be embedded as figures or spreadsheet files, but should be 
formatted using ‘Table object’ function in your word processing program. 
• Color and shading may not be used. Parts of the table can be highlighted using 
superscript, numbering, lettering, symbols or bold text, the meaning of which should be 
explained in a table legend. 
• Commas should not be used to indicate numerical values. 
e) Preparing additional files 
As the length and quantity of data is not restricted for many article types, authors can provide 
datasets, tables, movies, or other information as additional files. 
All Additional files will be published along with the accepted article. Do not include files 
such as patient consent forms, certificates of language editing, or revised versions of the main 
manuscript document with tracked changes. Such files, if requested, should be sent by email 
to the journal’s editorial email address, quoting the manuscript reference number. Please do 
not send completed patient consent forms unless requested. 
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Results that would otherwise be indicated as "data not shown" should be included as 
additional files. Since many web links and URLs rapidly become broken, BioMed Central 
requires that supporting data are included as additional files or deposited in a recognized 
repository. Please do not link to data on a personal/departmental website. Do not include any 
individual participant details. The maximum file size for additional files is 20 MB each, and 
files will be virus-scanned on submission. Each additional file should be cited in sequence 
within the main body of text. 
If additional material is provided, please list the following information in a separate section 
of the manuscript text: 
• File name (e.g. Additional file 1) 
• File format including the correct file extension for example .pdf, .xls, .txt, .pptx 
(including name and a URL of an appropriate viewer if format is unusual) 
• Title of data 
• Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced 
explicitly by file name within the body of the article, e.g. 'An additional movie file shows this 
in more detail [see Additional file 1]'. 
Items within additional files can be referenced in the main manuscript. However, please use 
the format set out in the following example: “See Supplementary Table 1, Additional File 1” 
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Appendix 2 
Protocol: 
Prevalence of non-communicable diseases in adults living with Human Immunodeficiency 
Virus: An Overview of Systematic Reviews. 
Principal investigator: Shahista Mustafa Jaffer 
Institution: Division of Epidemiology and Biostatistics 
Department of Global Health 
Stellenbosch University 
PO Box 19063 
Tygerberg 
7505 
South Africa 
Tel: +27 21 XXX XXX 
Fax: +27 21 XX XXX 
Supervisor: Prof. T Young 
Abbreviations and keywords 
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Abbreviations: 
NCD’s – Non-communicable diseases 
PLHIV – People living with HIV 
HIV – Human immunodeficiency virus  
AIDS – Acquired immunodeficiency syndrome 
ART – Antiretroviral Therapy 
DSM 5 - Diagnostic and Statistical Manual of Mental Disorders Fifth Edition 
FBG – Fasting Blood Glucose 
RBG - Random Blood Glucose 
OGTT - Oral Glucose Tolerance Test 
HbA1c - Glycated Hemoglobin 
LDL – Low Density Lipoproteins 
HDL - High Density Lipoproteins 
Keywords – Non-communicable diseases, People living with HIV, Human 
immunodeficiency virus, Antiretroviral Therapy  
Introduction 
Background 
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Human immunodeficiency virus (HIV) and Acquired immunodeficiency syndrome (AIDS) is 
a very well-known and well researched infectious disease. The global prevalence of HIV has 
been noted to have increased from 33.3 million people in 2010 to 36.7 million people on 
average by the end of 20151.  
Over the years, the use of combined Antiretroviral Therapy (ART) has reduced mortality 
from the disease despite it being incurable such that deaths from AIDS reduced from 
1.5million in 2010 to 1.1 million by the end of 20151. Also, life expectancy has increased due 
to the several mechanisms through which ART suppress viral replication, reduce the 
occurrence of opportunistic infections and improve immune function. It has been documented 
that the use of ART has led to a stability in the acquisition of new HIV infections amongst all 
ages such that the number of new infections dropped by a million people from 2.3 to 2.1 
million in 2010 and 2015 respectively1. This may aid the UNAIDS to achieve their 90-90-90 
goal of ending the AIDS epidemic. 
However, with increased life expectancy, aging is inevitable and thus the diseases associated 
with aging such as cardiovascular abnormalities, hypertension, insulin resistance/diabetes 
mellitus, cholesterol abnormalities, neurodegenerative disorders and so forth occur. Research 
suggests the emergence of such diseases much earlier in the HIV population than seen in the 
general population. For instance, a study in the US in 2010 showed that older HIV patients 
had a higher prevalence of hypertension 54%, hypertriglyceridemia 51% and low bone 
mineral density 39% compared to the general population of the same age 38%, 33% and 0% 
respectively 2. Another study done in Brazil suggested that there is premature aging in people 
living with HIV (PLHIV) by 15 years and that HIV is diagnosed at an early age between 18-
39years 3 leading to increased ART use in the older population and increasing the incidence 
of non-communicable diseases (NCD’s) such as hypertension, dyslipidemia, diabetes 
mellitus, obesity and depression with older age 3, 4, 5 due to prolonged exposure to ART. 
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Aging is not the only mechanism leading to the development of these NCD’s, these findings 
can be attributed to the disease process itself via its viral properties or the inflammation and 
reaction by the human body, and to the toxic effects of the ART which leads to ART induced 
endothelial dysfunction as shown by a systematic review done by Nduka CU et al 6. Also, 
studies reveal that the number of years since the diagnosis of HIV and the duration and type 
of ART received is crucial in the development of NCD’s. A study done in Mwanza region of 
Tanzania in 2013 showed that PLHIV on ART for more than 2 years had a prevalence of 
28.7% for hypertension while those naïve to ART had a prevalence of 5.3% 7. 
Another important aspect of the ART is the type of ART in question, it has been shown that 
people receiving a combination of Zidovudine/Lamivudine/Nevirapine (1st line treatment) 
are at an increased risk of hypertension while those receiving the non-standard 1st line 
treatment or the 2nd line drugs are at increased risk of Diabetes8. Long duration of ART and 
the use of protease inhibitors are also associated with increased risk of metabolic syndrome9. 
These findings are from clinical trials hence we may need more trials to certainly see the 
same effects in other populations.  
With a slow progress in the decline of new HIV infections amongst adults10, it has become a 
chronic problem and is being more associated with NCD’s at younger ages than in the 
general population. A huge burden of HIV of about 71% lies in the Sub-Saharan Africa 
(SSA) which is home to only about 12% of the global population11 with marked ART 
coverage over the last few years in different countries within the SSA10 as we aim to reach 
the 90-90-90 target set by the UNAIDS thus putting patients at the risk of developing NCD’s 
earlier indefinitely.  
Why is it important to do this review? 
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There have been many systematic reviews done on the prevalence of comorbidities in 
patients with HIV such as Type II diabetes mellitus, hypertension, dyslipidemia, neurological 
degeneration, chronic kidney diseases and thus we aim to consolidate all the available 
information in order to summarize the prevalence of co- and multi-morbidity in PLHIV and 
provide information to health institutions for planning of healthcare services for these patients 
in order to detect and treat early. Also, new studies need to be informed by the existing body 
of research. 
Objectives 
The aim of this overview is to determine the prevalence of one or more NCD’s - diabetes 
mellitus type 2, hypertension, dyslipidemia and depression – in adults with HIV on ART. 
Methods 
Definitions 
Multimorbidity is defined as the existence of two or more chronic medical conditions in a 
person that reduces his quality of life and functional abilities leading to increased hospital 
visits12. Thus, the presence of HIV along with two or more NCD’s will be described as 
multimorbidity while the presence of one chronic disease in a patient with HIV will be 
described as comorbidity. 
Diabetes mellitus type 2 is a chronic disease which is characterized by hyperglycemia/ raised 
blood sugar due to the body’s inability to effectively utilize insulin. Uncontrolled diabetes 
over time may lead to severe damage especially to the nerves and blood vessels. The 
diagnosis of diabetes us usually made by doing blood tests such as raised fasting blood 
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glucose (FBG) > 7mmol/L, random blood glucose of > 11.1mmol/L, glycated hemoglobin 
(HbA1c) > 6.5mmol/L or a two-hour oral glucose tolerance test (OGTT) of > 11.1mmol/L13. 
Hypertension is defined as persistently raised systolic and/or diastolic blood pressures of 
>140mmHg and >90mmHg respectively. Also, patients who are using any antihypertensive/
blood pressure lowering medicine suffer from hypertension14. 
Depression is part of a range of depressive disorders which are characterized by the presence 
of sad, empty, or irritable mood, accompanied by somatic and cognitive changes that 
significantly affect the individual's capacity to function. The Diagnostic and Statistical 
Manual of Mental Disorders Fifth Edition (DSM-5TM) has grouped the following under 
depressive disorders: disruptive mood dysregulation disorder, major depressive disorder 
(including major depressive episode), persistent depressive disorder (dysthymia), 
premenstrual dysphoric disorder, substance/medication-induced depressive disorder, and 
depressive disorder due to another medical condition, other specified depressive disorder, and 
unspecified depressive disorder15. 
Dyslipidemia is defined as elevated total serum cholesterol of > 5mmol/L or elevated low-
density lipoproteins (LDL) of > 3mmol/L or raised Triglycerides > 1.7mmol/L or low levels 
of high-density lipoproteins (HDL) < 1.2mmol/L. Self-reporting use of lipid lowering drugs 
can also be used to confirm the diagnosis16.  
Criteria for Considering Systematic Reviews for Inclusion 
Types of reviews and studies 
All systematic reviews determining the prevalence of NCD’s using cross-sectional studies in 
PLHIV. We will also review protocols for systematic reviews and if the reports are available 
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prior to submitting this overview, we will also include those results in our study. Systematic 
reviews are defined as studies that answer a research question by collecting and summarizing 
all empirical evidence that fits pre-specified eligibility criteria. It must have its objectives 
stated a priori and should have searched for studies on two or more databases including grey 
literature/unpublished work. Extracted data should have been analyzed, and a risk of bias 
assessed for each study with results presented appropriately17.  
Types of participants 
All adults above 18 years of age with HIV on treatment with any regimen of ART. We will 
not include pregnant women. 
Types of outcomes 
Primary outcomes 
Prevalence of two or more NCD’s namely diabetes mellitus, hypertension, dyslipidemia and 
depression in adults with HIV on ART. 
Secondary outcomes 
1. Prevalence of individual NCD’s specifically diabetes mellitus, hypertension, dyslipidemia
and depression in adults with HIV on ART. 
2. Distribution of these NCD’s according to demographics such as age, gender, duration and
type of ART. 
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Search Methods for Identification of Systematic Reviews 
We will search for existing systematic reviews in the Cochrane library, Medline, EMBASE, 
EBSCO host and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). 
For ongoing systematic reviews, we will search in Prospero. There will be no restrictions on 
language. 
Key words that will be used to conduct our search include “non-communicable diseases”; 
"Human immunodeficiency virus” OR “HIV”; "Antiretroviral therapy” OR “ART”; 
“Review” OR “Systematic review”; “Type 2 diabetes mellitus” OR “Diabetes mellitus” OR 
“Adult onset diabetes mellitus”; “Hypertension” OR “High blood pressure” OR “Raised 
blood pressure”; “Depression“ OR “Major depressive disorder” OR “MDD” OR “Depressive 
disorder” and “Dyslipidemia” OR “Hypercholesterolemia” OR “High blood cholesterol”. 
Systematic Review Selection, Data Collection, Quality Assessment and Analysis 
Selection of reviews 
Two authors will independently assess the eligibility of the reviews obtained from the 
electronic search. They will first screen through the titles and abstracts to determine 
potentially eligible articles. They will then obtain full texts of the relevant articles and apply 
the pre-specified eligibility criteria in order to be able to include them in the overview. Any 
discrepancy in the selection of studies will be resolved by discussion. 
Data extraction and management 
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Data will be extracted from the eligible systematic reviews by two authors independently into 
a predesigned and piloted data extraction form. Data that will be extracted from the reviews 
include: 
- Characteristics of the systematic reviews including the study designs and their
objectives. 
- Participants’ characteristics including age groups, gender and types/classes of ART’s
being used. 
- Setting
- Results of the studies i.e. the prevalence of each type of NCD assessed and the
prevalence of two or more NCD’s in PLHIV. 
Data will be summarized in characteristics of included review tables. Overlap between 
reviews will also be examined by preparing a matrix detailing reviews and studies included in 
the reviews.  
Assessment of methodological quality of included systematic reviews 
We will assess the methodological quality of each of the included systematic reviews using 
the AMSTAR 2 tool18 which is a revision of the AMSTAR tool in order to identify high 
quality 
Systematic reviews. AMSTAR 2 is a critical appraisal tool for systematic reviews that 
include randomized or non-randomized studies of health care interventions. It consists of 16 
domains which must be answered with a yes, partial yes or a no18. 
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We will not answer all the domains of the AMSTAR 2 tool as they focus on intervention 
studies while this overview focuses on systematic reviews of prevalence studies, thus we will 
use the domains that are applicable to appraising the quality of systematic reviews in general. 
We will not generate an overall score for each systematic review, rather we will consider the 
potential impact of an inadequate rating for each item. 
If there are any discrepancies in the data extracted by the two authors from the systematic 
reviews, then we will try to obtain the original article that was included in the systematic 
review and review its findings. Any disagreements between the authors will be solved by 
discussion. 
Data syntheses and analysis 
Because of the nature of the primary studies involved i.e. descriptive studies, we will provide 
a narrative summary of our findings considering all the participants, their NCD and ART 
status. Therefore, we plan to report on the prevalence of each type of NCD identified as well 
as the prevalence of two or more NCD’s in PLHIV with its 95% confidence interval. This 
will give us an overview of the challenge that the health care system faces whilst caring for 
HIV patients who also have other chronic diseases. 
Results 
Description of included reviews 
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Quality of included reviews (AMSTAR) 
Findings after combining the reviews 
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